UNIVERSITY of York

This is a repository copy of Matching the outcomes to treatment targets of exercise for low back pain: does it make a difference? Results of secondary analyses from individual patient data of randomised controlled trials and pooling of results across trials in comparative meta-analyses.

White Rose Research Online URL for this paper: <u>https://eprints.whiterose.ac.uk/189859/</u>

Version: Accepted Version

#### Article:

Wood, Lianne, Foster, Nadine E, Lewis, Martyn et al. (6 more authors) (2022) Matching the outcomes to treatment targets of exercise for low back pain: does it make a difference? Results of secondary analyses from individual patient data of randomised controlled trials and pooling of results across trials in comparative meta-analyses. Archives of Physical Medicine and Rehabilitation. ISSN 1532-821X

#### Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/

#### Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

## Archives of Physical Medicine and Rehabilitation

Matching the outcomes to treatment targets of exercise for low back pain: does it make a difference? Results of secondary analyses from individual patient data of randomised controlled trials and pooling of results across trials in comparative meta-analyses --Manuscript Draft--

Manuscript Number:	ARCHIVES-PMR-D-22-00146R2		
Article Type:	Original Research		
Keywords:	Low back pain; Exercise; treatment targets; secondary analysis; randomised controlled trials; composite outcomes		
Corresponding Author:	Lianne Wood, Ph.D Nottingham University Hospitals NHS Trust UNITED KINGDOM		
First Author:	Lianne Wood, Ph.D		
Order of Authors:	Lianne Wood, Ph.D		
	Nadine E Foster, DPhil		
	Martyn Lewis, PhD		
	Gert Bronfort, PhD		
	Erik J Groessl, PhD		
	Catherine E Hewitt, PhD		
	Gisela C Miyamoto, PhD		
	Silje E Reme, PhD		
	Annette Bishop, PhD		
Abstract:	Complex interventions, like exercise for non-specific low back pain (NSLBP), have many treatment targets. In randomised controlled trials (RCTs), matching the primary outcome to the exercise target(s) may provide greater standardised mean differences (SMDs) than using unmatched primary outcomes.		
	Objective These secondary analyses of previous RCTs aimed to explore whether using a single matched or composite outcome might impact the results of previous RCTs testing exercise for NSLBP. The first objective was to explore whether a single matched outcome generated a greater SMD when compared to the original unmatched primary outcome SMD. The second objective was to explore whether a composite measure, comprised of matched outcomes, generated a greater SMD when compared to combining the original primary outcome SMD.		
	Design, Setting and Participants We conducted exploratory secondary analyses of data from 1) five RCTs (n=1,033) that used an unmatched primary outcome but included (some) matched outcomes as secondary outcomes, and 2) four RCTs (n=864) that included multiple matched outcomes by developing composite outcomes. Intervention: Exercise compared to no exercise.		
	Main Outcome Measures: The composite consisted of standardised averaged matched outcomes. All analyses replicated the RCTs' primary outcome analyses.		
	Results		
	Of five RCTs, three had greater SMDs with matched outcomes (pooled effect SMD 0.30 (95% CI 0.04, 0.56), p=0.02) compared to an unmatched primary outcome (pooled effect SMD 0.19 (95% CI -0.03, 0.40) p=0.09). Of four composite outcome		

analyses, three RCTs had greater SMDs in the composite outcome (pooled effect SMD 0.28 (95%CI 0.05, 0.51) p=0.02) compared to the primary outcome (pooled effect SMD 0.24 (95%CI -0.04, 0.53) p=0.10).
Conclusion These exploratory analyses suggest that using an outcome matched to exercise treatment targets in NSLBP RCTs may produce greater SMDs than an unmatched primary outcome. Composite outcomes could offer a meaningful way of investigating superiority of exercise than single domain outcomes.

Versus Arthritis Primary Care Centre School of Medicine Keele University Keele Staffordshire ST5 5BG <u>I.wood2@keele.ac.uk</u> +44 7449732744 27-01-2022

Dr Leighton Chan and Dr Allen Heinemann

Editor-in-Chief

Archives of Physical Medicine and Rehabilitation

Dear Drs Chan and Heinemann,

Thank you for considering the included manuscript for publication in the Archives of Physical Medicine and Rehabilitation. The paper is entitled:

# "Matching the outcomes to treatment targets of exercise for low back pain: does it make a difference? Results of secondary analyses from individual patient data of randomised controlled trials and pooling of results across trials in comparative meta-analyses."

Exercise is a core treatment for persistent non-specific low back pain, but the use of a single primary outcome may not be sufficient to capture the often multiple treatment targets identified within an exercise intervention. This paper describes the results of two secondary analyses of individual participant data from existing RCTs to explore whether firstly, matching the primary outcome to the identified treatment targets, and secondly, whether a composite matched outcome in comparison to the original primary outcome, may change the results and conclusions of existing RCTs in persistent non-specific low back pain. These results suggest that exercise prescribers and trial developers should consider the treatment targets of their exercise intervention when selecting the most appropriate outcome.

I hereby certify that this paper consists of original, unpublished work which is not under consideration for publication elsewhere. All authors have read and confirmed that specified requirements for co-authorship are fulfilled. All authors are listed, and have contributed significantly to this work.

Yours sincerely,

Lianne Wood (on behalf of the author team)

Dear Dr Rundell,

#### Ms. Ref. No.: ARCHIVES-PMR-D-22-00146

Title: Matching the outcomes to treatment targets of exercise for low back pain: does it make a difference? Results of secondary analyses from individual patient data of randomised controlled trials and pooling of results across trials in comparative metaanalyses

Archives of Physical Medicine and Rehabilitation

We are very grateful for the constructive feedback provided by the editors and each of the external reviewers of this manuscript. We feel our manuscript has been improved as a result, and hope you will agree. We have addressed the Reviewers' comments point-by-point below. We provide a clean and a highlighted version to demonstrate changes in the revised manuscript. Our responses below are shown in blue to distinguish from the Reviewers comments. Page numbers mentioned in responses refer to the manuscript version with highlighted changes.

We hope the revised manuscript is suitable for publication and look forward to hearing from you soon.

Yours sincerely

The author team


#### **Reviewers' comments:**

Reviewer #1: Thank you for providing more clarity on the study as requested. The authors did a nice job of addressing/adding to the details in the methodology and analysis. In the Discussion - Implications for Clinicians and Researchers section, where it is stated: "We recommend that developers of exercise interventions consider logic models or programme development theory 36,37 in order to map and guide assessment of the mechanisms of action of their intervention, and the most likely outcomes to accurately measure the changes expected."...

1. Can the authors expand on this in more simple terms and provide an example of this approach? I would imagine that most of the clinical readership, and even many researchers would know very little about what the authors are referring to here.

Thank you for your comments. In response to this additional sentences have been added with an example figure to improve the understanding of the readership. "Previous intervention development has been exemplified by Hurley et al.37 and Kjaer et al.53 who provided detailed descriptions of their self-management and exercise programs (please see Figure 4 as an example program model), including the 'active' components of the intervention, the proposed determinants of change and the corresponding outcomes to capture the intended change. It should be noted that we do not suggest all RCTs need to consider this level of intervention development. However, considering the trial intervention through a visual model can help to alleviate research waste by ensuring capture of the most important outcomes, and may contribute to future knowledge of how these interventions may work." (In 379-388, page 17).

Figure 4: An example program model of the GLA:D Back intervention, the proposed patient achievements and the outcomes through the GLA:D Back program, and their theoretical links (reproduced from Kjaer et al., 2018, with permission)



2. I would suggest being more specific in the tables with regard to the outcome of "Pain" - I appreciate that the authors are referring to Pain Intensity (VAS), rather than say Pain Interference, or Pain Behavior, however, I recommend being more complete/thorough. Likewise - for Physical Function, I am presuming this means self-reported/patient-reported physical function rather than observer-rated/physical capacity testing of physical function -

but again, would suggest being more explicit between what is 'self-reported' and what is 'physical capacity' based measures...as the tables are listed now, both of these forms of tests are intermingled in the list, and it would be more helpful to see these broken down into self-reported measures and physical capacity measures.

Thank you for this comment. To improve the ease of understanding the tables, we have separated self-reported outcome measures from objectively reported outcome measures, in Table 1. We have also clarified pain and physical function scores for all included trials in Tables 1, 2 and 3. Table 1 and 2 outcomes have been further clarified to distinguish between self-reported outcomes and objectively recorded outcomes to improve transparency.

3. Reviewer #2: Thank you for addressing my original comments. I have one further query. For Table 3 it appears for the Moffett et al 2006 trial the primary outcome and composites did not detect a significant change; however, it is reported in the final column that using the composite resulted in a change in results. Could you please confirm this is correct?

Many thanks for your comment and identifying this error! Table 3 has been amended to reflect that "no change" occurred in the results of the first two matched trials. This has also been reinforced in the accompanying text as follows: "Three of the four analyses showed results with the composite outcome variable that had greater SMDs in favour of the exercise intervention25,26,28, **of which two 25,28** were (more) statistically significant in comparison to the original RCTs' primary outcome results. All analyses showed a smaller standard error when using the composite outcome. The use of the co-primary composite generated greater SMDs than the composite outcome. However, the co-primary composite generated greater SMDs (**not statistically significant**) than the primary outcome in one RCT,26 but this was not reproduced in the other RCT analysis.27" (In 232-240 page 11)

- 1. Running Head: Matching the outcomes to treatment targets of exercise
- 2. Title: Matching the outcomes to treatment targets of exercise for low back pain: does it make a difference? Results of secondary analyses from individual patient data of randomised controlled trials and pooling of results across trials in comparative meta-analyses
- Authors: Lianne Wood<sup>1,2</sup>, PhD; Nadine E Foster<sup>1\*</sup>, DPhil; Martyn Lewis<sup>1</sup>, PhD; Gert Bronfort<sup>3</sup> PhD; Erik J Groessl<sup>4</sup>, PhD; Catherine Hewitt<sup>5</sup>, PhD; Gisela C Miyamoto<sup>6</sup> PhD; Silje E. Reme, PhD<sup>7</sup> Annette Bishop<sup>1</sup>, PhD.
- 4. Authors Institutions at time of study: <sup>1</sup>Primary Care Centre Versus Arthritis, School of Medicine, Faculty of Medicine, Keele University, Newcastle-under-Lyme, UK; <sup>2</sup>Nottingham University Hospitals NHS Trust, Queens Medical Centre, Derby Road, Nottingham, UK; <sup>3</sup>Earl E Bakken Centre for Spirituality and Healing, University of Minnesota, USA; <sup>4</sup>University of California San Diego, Herbert Wertheim School of of Public Health and UCSD Health Services Research Centre; <sup>5</sup>York Trials Unit, Department of Health Sciences, University of York, UK; <sup>6</sup>Master's and Doctoral Program in Physical Therapy, Universidade Cidade de São Paulo, São Paulo, Brazil; <sup>7</sup>Department of Psychology, University of Oslo, Oslo, Norway \*NEF has changed affiliation to the STARS Education and Research Alliance, Surgical Treatment and Rehabilitation Service (STARS), The University of Queensland and Metro North Health, Herston, Brisbane, Queensland, Australia
- 5. Previous Presentation: The contents of this paper have been published as part of a doctoral thesis (examined by Viva November 2020), awarded June 2021; presented as a poster at The Society for Back Pain Research conference, Groningen, The Netherlands in November 2019.

- 6. Sources of Funding: L Wood's PhD was funded by the Primary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Faculty of Medicine and Health Sciences, Keele University. Prof NE Foster is a UK National Institute for Health Research (NIHR) Senior Investigator, and was supported by an NIHR Research Professorship (NIHR-RP-011-015). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health or Social Care.
- 7. Conflicts of Interest: There are none to declare.
- Corresponding author: L Wood, email: <u>I.wood2@keele.ac.uk</u>, Present address: Nottingham University Hospitals NHS Trust, Queens Medical Centre, Derby Road, Nottingham, NG 2UH, UK; +441159249924 ext 86217

### 9. Clinical trial registration numbers:

This is a secondary analysis of the following clinical trials:

- Miyamoto et al (2018): NCT02241538
- Bronfort et al. (2011) No registration number
- Moffett et al. (2006): ISRCTN48919562
- Harris et al. (2017) No registration number
- Tilbrook et al. (2011) Protocol published, no registration number
- Groessl et al. (2017) NCT02524158
- Shirato et al. (2010) Protocol published, no trial registration.

## **10. Author Contributions:**

The conceptualisation of this study was developed by AB, NEF, ML and LW;

Data curation was managed by LW;

Formal secondary analysis was performed by LW and ML;

Funding acquisition: LW's PhD was funded, in part, in order to analyse these data;

Supervision: NEF, ML and AB supervised LW during the analyses of these data;

Roles/Writing - original draft was written by LW and reviewed and edited by NEF,

AB, and ML; Writing – further review & editing was performed by GB, EG, GCM, CH,

SER.

## <u>Highlights</u>

- Exercise has multiple proposed treatment targets. Few RCTs match their outcomes to these targets.
- These analyses suggest that outcomes matched to exercise treatment targets may produce greater SMDs than outcomes that are not matched to exercise treatment targets
- Composite outcomes may generate greater SMDs and less uncertain
   estimates

1 **Title:** Matching the outcomes to treatment targets of exercise for low back pain: does

2 it make a difference? Results of secondary analyses from individual patient data of

3 randomised controlled trials and pooling of results across trials in comparative meta-

4 analyses

5

6 Abstract

7

#### 8 **Objective**

9 To explore whether using a single matched or composite outcome might impact the 10 results of previous randomised controlled trials (RCTs) testing exercise for non-11 specific low back pain (NSLBP). The first objective was to explore whether a single 12 matched outcome generated a greater standardised mean differences (SMD) when 13 compared to the original unmatched primary outcome SMD. The second objective was 14 to explore whether a composite measure, comprised of matched outcomes, generated 15 a greater SMD when compared to the original primary outcome SMD.

16

#### 17 Design

18 We conducted exploratory secondary analyses of data.

19

#### 20 Setting

Seven RCTs were included, of which two were based in the USA (University research
clinic, Veterans Affairs medical centre) and the UK (primary care clinics, nonmedical
centres). One each were based in Norway (clinics), Brazil (primary care), and Japan
(outpatient clinics).

26	Pa	rti	cip	ants

The first analysis comprised 1) five RCTs (n=1,033) that used an unmatched primary outcome but included (some) matched outcomes as secondary outcomes, and the second analysis comprised 2) four RCTs (n=864) that included multiple matched outcomes by developing composite outcomes.

31

#### 32 Intervention:

- 33 Exercise compared to no exercise.
- 34

#### 35 Main Outcome Measures:

The composite consisted of standardised averaged matched outcomes. All analysesreplicated the RCTs' primary outcome analyses.

38

#### 39 **Results**

Of five RCTs, three had greater SMDs with matched outcomes (pooled effect SMD 0.30 (95% CI 0.04, 0.56), p=0.02) compared to an unmatched primary outcome (pooled effect SMD 0.19 (95% CI -0.03, 0.40) p=0.09). Of four composite outcome analyses, three RCTs had greater SMDs in the composite outcome (pooled effect SMD 0.28 (95%CI 0.05, 0.51) p=0.02) compared to the primary outcome (pooled effect SMD 0.24 (95%CI -0.04, 0.53) p=0.10).

46

#### 47 Conclusions

48 These exploratory analyses suggest that using an outcome matched to exercise 49 treatment targets in NSLBP RCTs may produce greater SMDs than an unmatched

50	primary outcome. C	composite outcomes could offer a meaningful way of investigating	
51	superiority of exercise than single domain outcomes.		
52			
53			
54	Key words:	Low back pain, exercise, treatment targets, secondary analysis,	
55		randomised controlled trials, composite outcomes.	
56			
57			

#### 58 **Abbreviations:**

- 59 NSLBP non-specific low back pain
- 60 RCT randomised controlled trial
- 61 SMD standardised mean difference
- 62 ANOVA analysis of variance
- 63 ANCOVA analysis of covariance
- 64 WOMAC Western Ontario and McMaster Universities Osteoarthritis Index65

#### 66 Introduction

67

Persistent non-specific low back pain (NSLBP) is the leading cause of disability
globally,<sup>1,2</sup> with an estimated 540 million people worldwide experiencing NSLBP.<sup>3</sup>
Therapeutic exercise is the most widely recommended treatment for persistent
NSLBP<sup>4,5</sup> with moderate certainty evidence that it has clinically important benefits for
pain but small benefits for function.<sup>6–9</sup>

73

Exercise is a complex intervention with numerous components, such as biological,<sup>10</sup> 74 psychological and social,<sup>11</sup> as well as treatment interaction components.<sup>12</sup> Therefore, 75 there may be multiple potential treatment targets, where a treatment target is defined 76 as the goal or intention the treatment aims to influence.<sup>13</sup> Most randomised controlled 77 trials (RCTs) of exercise for persistent NSLBP do not specify their treatment targets.<sup>14</sup> 78 Literature regarding RCT design stipulates that the primary outcome should match the 79 rationale of the intervention,<sup>15,16</sup> yet outcome measures are often selected based on 80 core outcome domains<sup>17</sup> and/or patient preference. A recent systematic review<sup>18</sup> 81

demonstrated that most (74%) of the included RCTs of exercise in persistent NSLBP
used primary outcomes not reflective of the RCT's specified exercise treatment targets.
Further, most RCTs demonstrate only small differences between exercise and control
arms,<sup>7</sup> and therefore clinically important interventions may be overlooked, if these
benefits are related to the selection of the primary outcome.

87

88 In complex interventions, such as exercise, which frequently have more than one treatment target, the selection of a single primary outcome measure may be insufficient 89 to capture the benefits that can be achieved.<sup>19</sup> Watt et al.,<sup>19</sup> suggest that nominating a 90 single primary outcome in a RCT of a complex intervention may distort the overall 91 purpose. Composite outcomes, including two or more component outcome domains.<sup>20</sup> 92 may be more suitable than a single primary outcome in such RCTs, and may be better 93 able to demonstrate the effects of complex interventions. In addition, more meaningful 94 95 results of exercise RCTs for persistent NSLBP may be derived. However, due to the limited evidence on composite measures available for NSLBP, future research in this 96 area has been recommended.<sup>21</sup> 97

98

99 It is unknown whether using a matched primary outcome or composite outcome 100 (comprised of the specified treatment targets) might alter the findings of previous 101 RCTs.<sup>22</sup> This secondary analysis aimed to explore whether using a single matched or 102 composite outcome might impact the results of previous RCTs testing exercise for 103 persistent NSLBP. The first objective was to explore whether a single outcome, 104 matched to the identified exercise treatment targets, generated a greater standardised 105 mean difference (SMD) when compared to the original unmatched primary outcome

SMD. The second objective was to explore whether a composite measure, comprised
of more than one outcome matched to the identified exercise treatment targets,
generated a greater SMD when compared to the original primary outcome SMD.

109

110

### 111 Methods

112

113 Design

Exploratory secondary analyses of seven previous RCTs. A random effects metaanalysis (generated with RevMan 5.3) was used to compare: i) the overall effect of using an unmatched primary outcome with the first reported matched outcome, and ii) the overall effect of using a single primary outcome (matched or unmatched) with a composite (matched) outcome.

119

#### 120 Data Source

A recently completed systematic review of RCTs of exercise interventions compared 121 to no exercise in persistent NSLBP<sup>18</sup> informed the RCT sample for this study. 122 Treatment targets were extracted verbatim from the RCT published texts, where it was 123 124 clear the authors had described a rationale for how the exercise intervention was proposed to work, or what they had designed the exercise intervention to target. In the 125 review, RCTs were categorised into: a matched group, where the primary outcome 126 127 reflected one of the identified treatment targets; or an unmatched group, where the primary outcome did not reflect one of the identified treatment targets. The matching 128 process was subjective and performed by pairs of independent reviewers, as described 129

in Wood et al.<sup>18</sup> For each analysis, the authors of the identified RCTs were contacted
and the dataset requested. The first analysis identified RCTs within the unmatched
group that included secondary outcomes matched to the treatment targets. The second
analysis identified RCTs within both the matched and unmatched groups, where more
than one outcome reflected more than one stated exercise treatment target.

135

136

#### 137 Data Extraction

Information pertinent to these analyses was extracted as part of the systematic review process<sup>18</sup> by pairs of independent reviewers (see appendix 1). The stated treatment target(s) of the exercise intervention, the primary and secondary outcomes for each RCT, the outcomes that matched the stated exercise treatment targets, and the method of analysis performed on primary and secondary outcomes were extracted for each RCT (see Table 1).

144

145 Data Analysis

#### 146 Both Analyses:

SMDs and 95% confidence intervals were calculated for each primary and matched 147 148 secondary outcome for between-arm differences at the primary outcome time-point designated by the trial authors, or if no primary time-point was specified by the authors, 149 then the earliest time-point post-exercise-intervention. SMD statistics for all between-150 arm differences were reported as intervention minus control: positive SMDs indicating 151 higher values for the exercise intervention (lower for the control), and by contrast, 152 negative SMDs indicating lower values for the intervention (higher for the control). 153 Where some variables had point estimates scoring in the opposite direction to other 154

included variables, these were transformed so that all variables scored in the same
 direction.<sup>23,24</sup>

157

For linear mixed models<sup>25–28</sup> the data were transformed from wide to long format by 158 transforming the variables to cases and computing a new variable consisting of all 159 time-points relevant to that outcome. All outcomes of interest were converted to a 160 standardised variable (standardised z-score). Initial analyses aimed to replicate the 161 162 published data used for the primary outcome(s) and/or targeted secondary outcomes 163 where possible to do so. The replicated analysis was applied to the matched secondary outcome(s). Linear mixed model analyses include all time-points available 164 for the relevant outcome. Therefore values for all available time-points for the matched 165 secondary outcomes were also used and reported<sup>25-28</sup>. 166

167

#### 168 <u>Second Analysis Only:</u>

169 The second analysis created a composite outcome, comprised of multiple outcomes matched to the specified exercise treatment targets. For the creation of the composite 170 outcome, standardised composite outcomes were derived by computing a new 171 variable of the mean of the standardised outcome scores, matched to the treatment 172 targets, for each time-point.<sup>29</sup> A further analysis was performed where two primary 173 174 outcomes were specified, and both were matched to the treatment targets: a coprimary composite was developed by creating a new variable of the mean of the 175 standardised primary outcomes at each time point. Exploratory analysis compared the 176 results of the first nominated primary outcome in comparison to a targeted composite 177 outcome and the co-primary outcome composite. The method of analysis of between-178

- arm standardised differences replicated the initial primary time-point analysis. All
- analyses used Statistical Package for Social Science (SPSS) Statistics 24.

#### 182 **Results**

183

A summary of dataset acquisition and analysis is displayed in Figure 1, and details of
 included trials are presented in Table 1.

- 186
- Figure 1: Processes of identification of suitable trials for inclusion and
   analysis
- 189 Table 1: Included Trial Datasets
- 190

#### 191 First Analysis: The Difference between Matched and Unmatched Outcome SMDs

In the first analysis, lead authors from five RCTs<sup>25,28,30–32</sup> were contacted, and three datasets acquired. Two RCTs provided sufficient information within their published papers, resulting in five RCTs analysed (1,033 participants). Two RCTs compared yoga to usual care,<sup>30</sup> and a waitlist control,<sup>28</sup> three RCTs tested supervised exercise programs in comparison to a brief intervention<sup>32</sup>, a home exercise and manipulative arm<sup>25</sup>, and prescribed NSAIDS<sup>31</sup>.

198

Of the five RCTs included, three had greater SMDs and statistical significance in favour of exercise compared to a control-arm when a matched secondary outcome was used in comparison to an unmatched primary outcome<sup>25,28,31</sup> (see Table 2). Of the three full datasets analysed, two demonstrated larger, statistically significant effects in favour of exercise with at least one matched secondary outcome at the primary time-point(s), compared to an unmatched primary outcome<sup>25,28</sup>. The analysis of Harris et al.<sup>32</sup> did not demonstrate any statistically significant differences using any
of the outcomes, but the use of the matched secondary outcome generated a greater
SMD in favour of the exercise group than when using the unmatched primary outcome.
The analysis of Tilbrook et al.<sup>30</sup> was the only trial analysed to demonstrate greater
between-arm differences when using an unmatched primary outcome.

210

# Table 2: First analysis results demonstrating the difference between matched and unmatched outcome SMDs

213

The original results and secondary analyses of the five RCTs are summarised in Figure 215 2: a pooled SMD of 0.19 (95% CI -0.03, 0.40; p=0.09) was seen for the unmatched 216 primary outcome, in comparison to the SMD of 0.30 (95% CI 0.04, 0.56; p=0.02) for 217 the first reported matched outcome. The subgroup differences (primary outcome 218 compared to the first matched outcome) were not statistically significant (SMD 0.11; 219 95% CI -0.34, 0.57; p=0.51).

220

## Figure 2: Forest plot to demonstrate the pooled effect of the SMD for unmatched primary outcomes in comparison to matched secondary outcomes

223

224 <u>Second Analysis: Composite SMD calculations in comparison to Primary Outcome</u>
 225 <u>SMDs</u>

In the second analysis, lead authors from seven RCTs<sup>25-28,33-35</sup> were contacted, and

four authors shared their datasets.<sup>25–28</sup> Four RCTs were analysed (864 participants):

one compared differing Pilates dosages plus advice versus advice alone,<sup>27</sup> one 228 compared yoga to a waitlist,<sup>28</sup> one tested supervised exercise programs in a home 229 exercise versus a manipulative arm,<sup>25</sup> and one compared McKenzie exercises versus 230 a physiotherapy intervention.<sup>26</sup> The composite outcomes varied in composition with 231 three composite outcomes formed of six outcomes<sup>25–27</sup> and one composite comprised 232 of three outcomes<sup>28</sup>. For example, Groessl et al.<sup>28</sup> measured the outcomes of strength, 233 flexibility and pain relief in their RCT which were matched to the treatment targets of 234 increasing strength and flexibility and improving pain tolerance. Please see Table 3 for 235 236 more detail regarding composition of composite outcomes.

237

The composite analysis impacted the results of three of four RCTs,<sup>25,26,28</sup> as seen in 238 239 Table 3. Three of the four analyses showed results with the composite outcome variable that had greater SMDs in favour of the exercise intervention<sup>25,26,28</sup>, of which 240 two<sup>25,28</sup> were (more) statistically significant in comparison to the original RCTs' primary 241 outcome results. All analyses showed a smaller standard error when using the 242 composite outcome. The use of the co-primary composite generated greater SMDs 243 than the composite outcome. However, the co-primary composite generated greater 244 SMDs (not statistically significant) than the primary outcome in one RCT,<sup>26</sup> but this was 245 not reproduced in the other RCT analysis.<sup>27</sup> 246

247

Table 3: Second analysis results of composite SMD calculations compared to
 primary outcome SMDs

This is summarised in Figure 3 whereby a pooled SMD of 0.24 (95% CI -0.04, 0.53; p=0.10) was seen for the primary outcome in comparison to the SMD of 0.28 (95% CI 0.05, 0.51; p=0.02) for the matched composite outcome. The subgroup differences (primary outcome compared to matched composite) were not statistically significant (SMD 0.03 (95% CI -0.13, 0.20) p=0.86).

## Figure 3: Summary plot to demonstrate pooled SMD of primary outcome in comparison to composite outcome

258

259 Discussion

260

261 The results of these exploratory secondary analyses of previous RCTs of exercise for NSLBP suggest that it is possible that using a primary outcome matched to the 262 treatment targets of exercise may generate greater SMDs than a single unmatched 263 264 primary outcome. Further, using a composite outcome, matched to multiple exercise treatment targets, may give greater power to detect superiority of exercise over a non-265 266 exercise control. In three of five RCTs, a single matched outcome measure generated a greater SMD than the original unmatched primary outcome SMD, and would impact 267 the results of four RCTs. In two of four RCTs, a composite matched outcome would 268 impact the results in favour of exercise versus control. Our analyses provide some 269 support for matching the primary outcome to the treatment targets of the exercise 270 intervention, and for considering the use of a composite outcome in comparison to a 271 272 single outcome when multiple exercise targets are identified. Using a matched outcome may provide more clinically meaningful results, and will allow for identification of 273 274 treatment interventions that may be more effective than previously supposed.

275

276 Treatment targets may be described as intermediate variables or surrogate outcomes, as they may sit on the pathway to a patient relevant outcome such as pain or function. 277 278 However, this may not always be the case, and the treatment targets reported by the authors of these RCTs may not have been based on clear programme development 279 theory or logic modelling.<sup>36,37</sup> Many of the treatment targets identified by the RCT 280 authors were captured by some of their outcomes, but there were no published 281 intervention development or programme evaluation<sup>38</sup> papers for any of the included 282 283 RCTs within which to test the degree that these treatment targets were indeed the focus of their intervention. Thus, it is difficult to identify which of the treatment targets 284 may have been prioritised, or which may have been changed by the exercise 285 286 interventions. In exercise, where multiple treatment targets are common, it is challenging without clear intervention theory, to understand how the exercise 287 intervention may have exerted its effect. Heneghan et al.<sup>39</sup> caution against the use of 288 289 surrogate outcomes as primary outcomes, without a clear understanding of the impact and effect of these upon patient-relevant outcomes. In the field of exercise and 290 NSLBP, the effect surrogate outcomes have on important patient outcomes like pain, 291 function and quality of life is poorly understood. Furthermore, there is a lack of 292 understanding as to what mechanisms of effect underpin exercise interventions for 293 NSLBP.40,41 294

295

The results of these exploratory secondary data analyses provide some support for considering the use of a composite matched outcome rather than a single unmatched outcome in trials of exercise for NSLBP. The results contrast with those from Parkes et al.<sup>42</sup> who compared a composite outcome (the Western Ontario and McMaster

300 Universities Osteoarthritis Index [WOMAC] score, pain and rescue medication) to a single outcome (WOMAC pain) in knee osteoarthritis. Their composite outcome 301 demonstrated modest improvements in responsiveness when compared to WOMAC 302 303 pain alone, but these were not statistically significant. While composite outcomes are uncommon as primary outcome measures in RCTs in the field of NSLBP, they are 304 frequently used in cardiovascular medicine, and have both advantages and 305 disadvantages. The use of a composite outcome can reduce the sample size,<sup>43,44</sup> which 306 is beneficial both for the recruitment period and associated costs of RCTs.45,46 307 308 However, in cardiovascular disease when a composite outcome included the outcome measures of most importance to patients, composite outcomes were less likely to 309 demonstrate a moderate treatment effect.<sup>46</sup> Moreover, there is a risk of overestimation 310 311 of treatment impact and effect when using composite outcomes if the component outcomes are not reported completely, leading to incorrect interpretation of the 312 results.<sup>39</sup> If the use of composite outcomes is to be considered in NSLBP, composite 313 314 outcomes would need to be chosen based on sound rationale. Furthermore, all outcomes selected to be included in the composite should individually be expected to 315 demonstrate an important effect, as any outcome that does not will dilute the overall 316 effect. Hence, composites make sense if the targeted outcomes all contribute to an 317 318 important treatment effect and are responsive to change. This proposal is supported 319 by our results that show the co-primary (matched) analysis produced the overall highest SMDs (greater than the composite). 320

321

Most RCTs of exercise for LBP appear to use a recommended core outcome domain<sup>47</sup> as a primary outcome.<sup>18</sup> Core outcome domains are necessary to allow for comparison of results across multiple datasets, and are useful for combined evidence approaches

325 such as meta-analysis. However, the authors of the LBP core outcome set highlight that the agreed domains do not restrict measurement or the choice of primary outcome. 326 but "mandate collection and reporting of the core outcome set alongside the outcomes 327 of interest".<sup>17</sup> It could be argued that prioritising pain or back-related disability as the 328 primary outcome domain in RCTs testing exercise for persistent NSLBP may not 329 accurately reflect the benefits of exercise, if these outcome domains do not match the 330 range of treatment targets of the intervention. The challenge of outcome measure 331 selection is encapsulated by Coster et al.,<sup>48</sup> "The ultimate value of a RCT ...will be 332 directly tied to how well the selected outcome measure matches the researcher's 333 understanding of what he or she expects to change, to what degree it is expected to 334 335 change, over what period of time this change will happen and how that change can 336 best be identified". As exercise is a complex intervention with multiple potential treatment targets, there are multiple possible outcomes that could be used, but multiple 337 outcomes should be interpreted with caution.<sup>49</sup> The proposed treatment targets of the 338 339 intervention should influence the selection of the primary outcome, from which the minimally important difference is used to calculate the sample size.<sup>49</sup> Literature 340 regarding RCT design stipulates that the primary outcome should match the rationale 341 of the intervention.<sup>16,50</sup> The results of this analysis suggest that matching the primary 342 343 outcome to the treatment targets of the intervention may generate greater SMDs in 344 favour of exercise, and that a composite outcome comprised of the most important treatment targets could generate greater SMDs with smaller standard errors in favour 345 of exercise. A matched 'targeted' composite or single outcome may provide the RCT 346 347 team with the best chance of detecting the benefits of exercise compared to a control or comparator, as well as providing a clear framework for future testing of how exercise 348 may potentially achieve its effects. This may have clinical implications given we have 349

limited understanding of what components or targets of exercise are most influential increating change in outcomes of importance.

352

#### 353 Strengths and Limitations

354

This is the first study to explore the relationship between matched outcomes or 355 composite outcomes and the treatment targets of the exercise intervention in RCT 356 datasets of exercise for NSLBP. A strength of this study is the individual patient data 357 358 acquisition of seven previously published RCTs which allowed secondary analysis of 359 the data and generation of new composite variables. The analysis methods replicated the primary analysis method used by the trial teams of the individual RCTs, and this 360 ensured the data were comparable, strengthening the results of this analysis. These 361 RCTs were selected from a sample of RCTs included in a systematic review,<sup>18</sup> which 362 may have been subject to publication bias. The main limitation is that this was an 363 exploratory secondary analysis of a small number of RCT datasets. SMDs were chosen 364 as a means to compare outcome estimates of different outcomes, but this may limit the 365 interpretability of the results as the SMD can be highly influenced by the SD of the 366 outcome data.<sup>51</sup> 367

368

#### 369 Implications for Clinicians and Researchers

370

371 Greater SMDs in favour of exercise interventions in RCTs for persistent NSLBP may 372 be derived from a combination of outcome measures rather than one alone in 373 determining treatment success, similar to the approach in the field of osteoarthritis. <sup>52,21</sup>

374 Greater SMD results may help to identify clinically meaningful treatments that may have 375 previously been overlooked due to selection of an unmatched primary outcome. Validation of these results is required in a larger sample of exercise trials in NSLBP, 376 and it would be interesting to explore the same issues for other complex interventions 377 for NSLBP, and for other conditions. Clinicians and developers of exercise 378 interventions may wish to consider what their exercise intervention targets, in order to 379 select the most appropriate outcomes for that intervention. Further, it may be more 380 beneficial for developers of RCT interventions to use a composite outcome comprised 381 382 of the most important outcomes targeted to the intervention being tested. We recommend that developers of exercise interventions consider logic models or 383 384 programme development theory<sup>36,37</sup> in order to map and guide assessment of the 385 mechanisms of action of their intervention, and the most likely outcomes to accurately measure the changes expected. Previous intervention development has been 386 exemplified by Hurley et al.<sup>37</sup> and Kjaer et al.<sup>53</sup> who provided detailed descriptions of 387 388 their self-management and exercise programs (please see Figure 4 as an example program model), including the 'active' components of the intervention, the proposed 389 determinants of change and the corresponding outcomes to capture the intended 390 change. It should be noted that we do not suggest all RCTs need to consider this level 391 of intervention development. However, considering the trial intervention through a 392 visual model can help to alleviate research waste by ensuring capture of the most 393 important outcomes, and may contribute to future knowledge of how these 394 interventions may work. 395

396 Figure 4: An example program model of the GLA:D Back intervention, the 397 proposed patient achievements and the outcomes through the GLA:D Back

398 program, and their theoretical links (reproduced from Kjaer et al.,<sup>53</sup> with 399 permission)

400

401 **Conclusion** 

402

This study provides initial support that using i) a primary outcome matched to the treatment targets of the intervention may generate greater SMDs, and using ii) a composite outcome comprised of several outcomes matched to the exercise treatment targets, may generate greater SMDs and tighter estimates in favour of exercise interventions in comparison to a non-exercise arm in persistent NSLBP. Exercise prescribers and developers should consider the treatment targets of their intervention when selecting the most appropriate outcome(s).

#### 411 **References**

- Buchbinder R, van Tulder M, Öberg B, et al. Low back pain: a call for action.
   *Lancet.* 2018;391(10137):2384-2388.
- 414 2. Hoy D, March L, Brooks P, et al. Measuring the global burden of low back
  415 pain. *Best Pract Res Clin Rheumatol.* 2010;24:155-165.
- 416 3. Hoy D, March L, Brooks P, et al. The global burden of low back pain: estimates
  417 from the Global Burden of Disease 2010 study. *Ann Rheum Dis.* 2014;0:1-7.
- 418 4. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for
- 419 non-surgical treatment of patients with recent onset low back pain or lumbar
  420 radiculopathy. *Eur Spine J.* 2018;27:60-75.
- 421 5. National Institute for Health and Care Excellence. *Low Back Pain and Sciatica*
- *in over 16s: Assessment and Management Assessment and Non-Invasive*
- 423 Treatments Low Back Pain and Sciatica in over 16s.; 2016.
- 424 6. Babatunde OO, Jordan JL, Van der Windt DA, Hill JC, Foster NE, Protheroe J.
- 425 Effective treatment options for musculoskeletal pain in primary care: A
- 426 systematic overview of current evidence. Fleckenstein J, ed. *PLoS One*.
- 427 2017;12(6):e0178621.
- 428 7. Hayden JA, Ellis J, Ogilvie R, Malmivaara A, van Tulder MMW. Exercise

429 therapy for chronic low back pain. *Cochrane Database Syst Rev.* 

- 430 2021;CD009790:in press.
- 431 8. Hayden JA, Wilson MN, Stewart S, et al. Exercise treatment effect modifiers in
- 432 persistent low back pain: an individual participant data meta-analysis of 3514
- 433 participants from 27 randomised controlled trials On behalf of Chronic Low
- 434 Back Pain IPD Meta-Analysis Group. *Br J Sport Med*. 2019;0:1-16.
- 435 9. Searle A, Spink M, Ho A, Chuter V. Exercise interventions for the treatment of

- chronic low back pain: a systematic review and meta-analysis of randomised
  controlled trials. *Clin Rehabil.* 2015;29(12):1155-1167.
- 438 10. Naugle KM, Naugle KE, Riley JL, III. Reduced Modulation of Pain in Older
- 439 Adults After Isometric and Aerobic Exercise. *J Pain.* 2016;17(6):719-728.
- 440 11. Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH. Physical
- 441 activity and exercise for chronic pain in adults: an overview of Cochrane

442 Reviews. *Cochrane Database Syst Rev.* 2017;4(4):CD011279.

- 12. Steiger F, Wirth B, de Bruin ED, Mannion AF. Is a positive clinical outcome
- 444 after exercise therapy for chronic non-specific low back pain contingent upon a
- 445 corresponding improvement in the targeted aspect(s) of performance? A
- 446 systematic review. *Eur Spine J.* 2012;21(4):575-598.
- In Emergent Literacy Intervention. *Semin Speech Lang.* 2007;28(1):014-024.
- 449 14. Wood L, Ogilvie R, Hayden JA. Specifying the treatment targets of exercise
  450 interventions: do we? *Br J Sports Med.* 2020;54(20):1235-1236.
- 451 15. Chiarotto A, Terwee CB, Ostelo RW. Choosing the right outcome
- 452 measurement instruments for patients with low back pain. *Best Pract Res Clin*
- 453 *Rheumatol.* 2016;30(6):1003-1020.
- 454 16. Craig P, Matthews L, Moore L, Simpson S, Skivington K. Updated guidance:
- developing and evaluating complex interventions [draft of updated guidance forconsultation]. 2019:99.
- 457 17. Chiarotto A, Deyo RA, Terwee CB, et al. Core outcome domains for clinical
  458 trials in non-specific low back pain. *Eur Spine J*. 2015;24(6):1127-1142.
- 459 18. Wood L, Foster NE, Lewis M, Bishop A. Exercise interventions for persistent
- 460 non-specific low back pain does matching outcomes to treatment targets

461 make a difference? A systematic review and meta-analysis. *J Pain*.

462 2021;22(2):107-126.

- 463 19. Watt H, Harris M, Noyes J, et al. Development of a composite outcome score
  464 for a complex intervention measuring the impact of Community Health
- 465 Workers. *Trials*. 2015;16(1):107.
- 466 20. Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC. Definition,
- 467 reporting, and interpretation of composite outcomes in clinical trials:
- 468 Systematic review. *BMJ*. 2010;341(7769):381.
- 469 21. Deyo RA, Dworkin SF, Amtmann D, et al. Report of the NIH Task Force on
- 470 research standards for chronic low back pain. *J Pain*. 2014;15(6):569-585.
- 471 22. Campbell N, Murray E. Designing and evaluating complex interventions to
- 472 improve health care. *BMJ*. 2007;334(7591):455-459.
- 23. Pogue J, Devereaux PJ, Thabane L, Yusuf S. Designing and analyzing clinical
- trials with composite outcomes: Consideration of possible treatment
- differences between the individual outcomes. *PLoS One*. 2012;7(4).
- 476 24. Sankoh AJ, D'Agostino RB, Huque MF. Efficacy endpoint selection and
- 477 multiplicity adjustment methods in clinical trials with inherent multiple endpoint
- 478 issues. *Stat Med*. 2003;22(20):3133-3150.
- 479 25. Bronfort G, Maiers MJ, Evans RL, et al. Supervised exercise, spinal
- 480 manipulation, and home exercise for chronic low back pain: A randomized
- 481 clinical trial. *Spine J*. 2011;11(7):585-598.
- 482 26. Moffett JK, Jackson DA, Gardiner ED, et al. Randomized trial of two
- 483 physiotherapy interventions for primary care neck and back pain patients:
- 484 "McKenzie" vs brief physiotherapy pain management. *Rheumatology*.
- 485 2006;45(12):1514-1521.

- 486 27. Miyamoto GC, Franco KFM, van Dongen JM, et al. Different doses of Pilates-
- 487 based exercise therapy for chronic low back pain: a randomised controlled trial
  488 with economic evaluation. *Br J Sports Med.* 2018;52:859-868.
- 489 28. Groessl EJ, Liu L, Chang DG, et al. Yoga for Military Veterans with Chronic
- 490 Low Back Pain: A Randomized Clinical Trial. *Am J Prev Med.* 2017;53(5):599491 608.
- 492 29. Song M-K, Lin F-C, Ward S, Fine J, Hill C. Composite Variables: When and
  493 How. *Nurs Res.* 2013;62(1):45-49.
- 494 30. Tilbrook HE, Cox H, Hewitt CE, et al. Yoga for Chronic Low Back Pain. Ann
  495 Intern Med. 2011;155(9):569-578.
- 496 31. Shirado O, Doi T, Akai M, et al. Multicenter randomized controlled trial to
  497 evaluate the effect of home-based exercise on patients with chronic low back
- 498 pain: the Japan low back pain exercise therapy study. *Spine (Phila Pa 1976)*.
  499 2010;35(17):E811-9.
- 500 32. Harris A, Moe TF, Eriksen HR, et al. Brief intervention, physical exercise and
- 501 cognitive behavioural group therapy for patients with chronic low back pain
- 502 (The CINS trial). *Eur J Pain (United Kingdom)*. 2017;21(8):1397-1407.
- 33. Maul I, Läubli T, Oliveri M, Krueger H. Long-term effects of supervised physical
  training in secondary prevention of low back pain. *Eur Spine J*.
- 505 2005;14(6):599-611.
- 506 34. Hildebrandt VH, Roper KI, Van den B, Douwes M, Van den Heuvel SG, Van
- 507 Buuren S. Cesar therapy is temporarily more effective than a standard
- treatment from the general practitioner in patients with chronic aspecific lower
- 509 back pain; randomized, controlled and blinded study with a I year follow-up.
- 510 *Ned Tijdschr Geneeskd*. 2000;144(47 PG-2258-2264):2258-2264.

511	35.	Chen HM, Wang HH, Chen CH, Hu HM. Effectiveness of a stretching exercise
512		program on low back pain and exercise self-efficacy among nurses in Taiwan:
513		A randomized clinical trial. Pain Manag Nurs. 2014;15(1):283-291.
514	36.	Rohwer A, Pfadenhauer L, Burns J, et al. Logic models help make sense of
515		complexity in systematic reviews and health technology assessments. J Clin
516		Epidemiol. 2017;83:37-47.
517	37.	Hurley DA, Murphy LC, Hayes D, et al. Using intervention mapping to develop
518		a theory-driven, group-based complex intervention to support self-
519		management of osteoarthritis and low back pain (SOLAS). Implement Sci.
520		2016;11(1):56.
521	38.	Moore GF, Audrey S, Barker M, et al. Process evaluation of complex
522		interventions: Medical Research Council guidance. BMJ. 2015;350(19
523		6):h1258-h1258.
524	39.	Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to
525		translate into benefits for patients. <i>Trials</i> . 2017;18(1):1-7.
526	40.	Helmhout PH, Staal JB, Maher CG, Petersen T, Rainville J, Shaw WS.
527		Exercise therapy and low back pain: insights and proposals to improve the
528		design, conduct, and reporting of clinical trials. Spine (Phila Pa 1976).
529		2008;33(16):1782-1788.
530	41.	Rainville J, Hartigan C, Martinez E, Limke J, Jouve C, Finno M. Exercise as a
531		treatment for chronic low back pain. Spine J. 2004;4(1):106-115.
532	42.	Parkes MJ, Callaghan MJ, Tive L, Lunt M, Felson DT. Responsiveness of
533		Single versus Composite Measures of Pain in Knee Osteoarthritis. $J$
534		Rheumatol. 2018;45(9):1308-1315.
535	43.	Ross S. Composite outcomes in randomized clinical trials: arguments for and

- 536 against. *Am J Obstet Gynecol*. 2007;196(2):119.e1-119.e6.
- 537 44. Vaanholt MCW, Kok MM, von Birgelen C, Weernink MGM, van Til JA. Are
  538 component endpoints equal? A preference study into the practice of composite
  539 endpoints in clinical trials. *Heal Expect.* 2018;21(6):1046-1055.
- 540 45. Ferreira-González I, Permanyer-Miralda G, Busse JW, et al. Methodologic
- 541 discussions for using and interpreting composite endpoints are limited, but still
- identify major concerns. *J Clin Epidemiol*. 2007;60:651-657.
- 543 46. Ferreira-González I, Busse JW, Heels-Ansdell D, et al. Problems with use of
  544 composite end points in cardiovascular trials: Systematic review of randomised
- 545 controlled trials. *BMJ*. 2007;334(7597):786-788.
- 546 47. Chiarotto A, Terwee CB, Deyo RA, et al. A core outcome set for clinical trials
  547 on non-specific low back pain: study protocol for the development of a core
  548 domain set. *Trials*. 2014;15(1):511.
- 549 48. Coster WJ. Making the Best Match: Selecting Outcome Measures for Clinical
- 550 Trials and Outcome Studies MeSH TERMS clinical trials as topic decision
- 551 making guidelines as topic outcome assessment (health care) treatment
- 552 outcome. *Am J Occup Ther*. 2013;67:162-170.
- 49. van Tulder M, Malmivaara A, Hayden J, Koes B. Statistical significance versus
  clinical importance: trials on exercise therapy for chronic low back pain as
  example. *Spine (Phila Pa 1976)*. 2007;32(16):1785-1790.
- 556 50. Chiarotto A, Ostelo RW, Turk DC, Buchbinder R, Boers M. Core outcome sets 557 for research and clinical practice. *Brazilian J Phys Ther*. 2017;21(2):77-84.
- 558 51. Faraone S V. Interpreting estimates of treatment effects: Implications for
  559 managed care. *P T*. 2008;33(12).
- 560 52. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an

561 international initiative to improve outcome measurement in rheumatology.

562 *Trials*. 2007;8:38.

- 563 53. Kjaer P, Kongsted A, Ris I, et al. GLA:D ® Back group-based patient education
- 564 integrated with exercises to support self-management of back pain -
- 565 Development, theories and scientific evidence Development, t. *BMC*
- 566 *Musculoskelet Disord*. 2018;19(1):1-21.
- 567

### 568 Figure Legends

569

570 Figure 1: Processes of identification of suitable trials for inclusion and analysis

571 Figure 2: Forest plot to demonstrate the pooled effect of the SMD for unmatched

572 primary outcomes in comparison to matched secondary outcomes

- 573 Figure 3: Summary plot to demonstrate pooled SMD of primary outcome in
- 574 comparison to composite outcome
- 575 Figure 4: An example program model of the GLA:D Back intervention, the proposed
- 576 patient achievements and the outcomes through the GLA:D Back program, and their
- 577 theoretical links (reproduced from Kjaer et al., 2018, with permission)

578

1 **Title:** Matching the outcomes to treatment targets of exercise for low back pain: does

2 it make a difference? Results of secondary analyses from individual patient data of

3 randomised controlled trials and pooling of results across trials in comparative meta-

4 analyses

5

6 Abstract

7

#### 8 **Objective**

9 To explore whether using a single matched or composite outcome might impact the 10 results of previous randomised controlled trials (RCTs) testing exercise for non-11 specific low back pain (NSLBP). The first objective was to explore whether a single 12 matched outcome generated a greater standardised mean differences (SMD) when 13 compared to the original unmatched primary outcome SMD. The second objective was 14 to explore whether a composite measure, comprised of matched outcomes, generated 15 a greater SMD when compared to the original primary outcome SMD.

16

#### 17 Design

18 We conducted exploratory secondary analyses of data.

19

#### 20 Setting

Seven RCTs were included, of which two were based in the USA (University research
clinic, Veterans Affairs medical centre) and the UK (primary care clinics, nonmedical
centres). One each were based in Norway (clinics), Brazil (primary care), and Japan
(outpatient clinics).

The first analysis comprised 1) five RCTs (n=1,033) that used an unmatched primary outcome but included (some) matched outcomes as secondary outcomes, and the second analysis comprised 2) four RCTs (n=864) that included multiple matched outcomes by developing composite outcomes.

31

#### 32 Intervention:

- 33 Exercise compared to no exercise.
- 34

#### 35 Main Outcome Measures:

The composite consisted of standardised averaged matched outcomes. All analysesreplicated the RCTs' primary outcome analyses.

38

#### 39 **Results**

Of five RCTs, three had greater SMDs with matched outcomes (pooled effect SMD 0.30 (95% CI 0.04, 0.56), p=0.02) compared to an unmatched primary outcome (pooled effect SMD 0.19 (95% CI -0.03, 0.40) p=0.09). Of four composite outcome analyses, three RCTs had greater SMDs in the composite outcome (pooled effect SMD 0.28 (95%CI 0.05, 0.51) p=0.02) compared to the primary outcome (pooled effect SMD 0.24 (95%CI -0.04, 0.53) p=0.10).

46

#### 47 Conclusions

These exploratory analyses suggest that using an outcome matched to exercisetreatment targets in NSLBP RCTs may produce greater SMDs than an unmatched

- 50 primary outcome. Composite outcomes could offer a meaningful way of investigating
- 51 superiority of exercise than single domain outcomes.
- 52
- Key words: Low back pain, exercise, treatment targets, secondary analysis,
  randomised controlled trials, composite outcomes.

#### 57 Abbreviations:

- 58 NSLBP non-specific low back pain
- 59 RCT randomised controlled trial
- 60 SMD standardised mean difference
- 61 ANOVA analysis of variance
- 62 ANCOVA analysis of covariance
- WOMAC Western Ontario and McMaster Universities Osteoarthritis Index
   64

65 Introduction

66

Persistent non-specific low back pain (NSLBP) is the leading cause of disability globally,<sup>1,2</sup> with an estimated 540 million people worldwide experiencing NSLBP.<sup>3</sup> Therapeutic exercise is the most widely recommended treatment for persistent NSLBP<sup>4,5</sup> with moderate certainty evidence that it has clinically important benefits for pain but small benefits for function.<sup>6–9</sup>

72

Exercise is a complex intervention with numerous components, such as biological,<sup>10</sup> 73 74 psychological and social,<sup>11</sup> as well as treatment interaction components.<sup>12</sup> Therefore, there may be multiple potential treatment targets, where a treatment target is defined 75 as the goal or intention the treatment aims to influence.<sup>13</sup> Most randomised controlled 76 trials (RCTs) of exercise for persistent NSLBP do not specify their treatment targets.<sup>14</sup> 77 Literature regarding RCT design stipulates that the primary outcome should match the 78 rationale of the intervention,<sup>15,16</sup> yet outcome measures are often selected based on 79 core outcome domains<sup>17</sup> and/or patient preference. A recent systematic review<sup>18</sup> 80

demonstrated that most (74%) of the included RCTs of exercise in persistent NSLBP
used primary outcomes not reflective of the RCT's specified exercise treatment targets.
Further, most RCTs demonstrate only small differences between exercise and control
arms,<sup>7</sup> and therefore clinically important interventions may be overlooked, if these
benefits are related to the selection of the primary outcome.

86

87 In complex interventions, such as exercise, which frequently have more than one treatment target, the selection of a single primary outcome measure may be insufficient 88 to capture the benefits that can be achieved.<sup>19</sup> Watt et al.,<sup>19</sup> suggest that nominating a 89 single primary outcome in a RCT of a complex intervention may distort the overall 90 purpose. Composite outcomes, including two or more component outcome domains.<sup>20</sup> 91 may be more suitable than a single primary outcome in such RCTs, and may be better 92 able to demonstrate the effects of complex interventions. In addition, more meaningful 93 94 results of exercise RCTs for persistent NSLBP may be derived. However, due to the limited evidence on composite measures available for NSLBP, future research in this 95 area has been recommended.<sup>21</sup> 96

97

98 It is unknown whether using a matched primary outcome or composite outcome 99 (comprised of the specified treatment targets) might alter the findings of previous 100 RCTs.<sup>22</sup> This secondary analysis aimed to explore whether using a single matched or 101 composite outcome might impact the results of previous RCTs testing exercise for 102 persistent NSLBP. The first objective was to explore whether a single outcome, 103 matched to the identified exercise treatment targets, generated a greater standardised 104 mean difference (SMD) when compared to the original unmatched primary outcome

SMD. The second objective was to explore whether a composite measure, comprised
of more than one outcome matched to the identified exercise treatment targets,
generated a greater SMD when compared to the original primary outcome SMD.

108

109

#### 110 Methods

111

112 Design

Exploratory secondary analyses of seven previous RCTs. A random effects metaanalysis (generated with RevMan 5.3) was used to compare: i) the overall effect of using an unmatched primary outcome with the first reported matched outcome, and ii) the overall effect of using a single primary outcome (matched or unmatched) with a composite (matched) outcome.

118

#### 119 Data Source

A recently completed systematic review of RCTs of exercise interventions compared 120 to no exercise in persistent NSLBP<sup>18</sup> informed the RCT sample for this study. 121 Treatment targets were extracted verbatim from the RCT published texts, where it was 122 123 clear the authors had described a rationale for how the exercise intervention was proposed to work, or what they had designed the exercise intervention to target. In the 124 review, RCTs were categorised into: a matched group, where the primary outcome 125 126 reflected one of the identified treatment targets; or an unmatched group, where the primary outcome did not reflect one of the identified treatment targets. The matching 127 process was subjective and performed by pairs of independent reviewers, as described 128

in Wood et al.<sup>18</sup> For each analysis, the authors of the identified RCTs were contacted
and the dataset requested. The first analysis identified RCTs within the unmatched
group that included secondary outcomes matched to the treatment targets. The second
analysis identified RCTs within both the matched and unmatched groups, where more
than one outcome reflected more than one stated exercise treatment target.

134

135

#### 136 Data Extraction

Information pertinent to these analyses was extracted as part of the systematic review process<sup>18</sup> by pairs of independent reviewers (see appendix 1). The stated treatment target(s) of the exercise intervention, the primary and secondary outcomes for each RCT, the outcomes that matched the stated exercise treatment targets, and the method of analysis performed on primary and secondary outcomes were extracted for each RCT (see Table 1).

143

144 Data Analysis

#### 145 Both Analyses:

SMDs and 95% confidence intervals were calculated for each primary and matched 146 147 secondary outcome for between-arm differences at the primary outcome time-point designated by the trial authors, or if no primary time-point was specified by the authors, 148 then the earliest time-point post-exercise-intervention. SMD statistics for all between-149 arm differences were reported as intervention minus control: positive SMDs indicating 150 higher values for the exercise intervention (lower for the control), and by contrast, 151 negative SMDs indicating lower values for the intervention (higher for the control). 152 Where some variables had point estimates scoring in the opposite direction to other 153

included variables, these were transformed so that all variables scored in the same
 direction.<sup>23,24</sup>

156

For linear mixed models<sup>25–28</sup> the data were transformed from wide to long format by 157 transforming the variables to cases and computing a new variable consisting of all 158 time-points relevant to that outcome. All outcomes of interest were converted to a 159 standardised variable (standardised z-score). Initial analyses aimed to replicate the 160 published data used for the primary outcome(s) and/or targeted secondary outcomes 161 162 where possible to do so. The replicated analysis was applied to the matched secondary outcome(s). Linear mixed model analyses include all time-points available 163 for the relevant outcome. Therefore values for all available time-points for the matched 164 secondary outcomes were also used and reported<sup>25-28</sup>. 165

166

#### 167 <u>Second Analysis Only:</u>

168 The second analysis created a composite outcome, comprised of multiple outcomes matched to the specified exercise treatment targets. For the creation of the composite 169 outcome, standardised composite outcomes were derived by computing a new 170 variable of the mean of the standardised outcome scores, matched to the treatment 171 targets, for each time-point.<sup>29</sup> A further analysis was performed where two primary 172 173 outcomes were specified, and both were matched to the treatment targets: a coprimary composite was developed by creating a new variable of the mean of the 174 standardised primary outcomes at each time point. Exploratory analysis compared the 175 results of the first nominated primary outcome in comparison to a targeted composite 176 outcome and the co-primary outcome composite. The method of analysis of between-177

- arm standardised differences replicated the initial primary time-point analysis. All
- analyses used Statistical Package for Social Science (SPSS) Statistics 24.

#### 181 **Results**

182

A summary of dataset acquisition and analysis is displayed in Figure 1, and details ofincluded trials are presented in Table 1.

- 185
- Figure 1: Processes of identification of suitable trials for inclusion and
   analysis
- 188 Table 1: Included Trial Datasets
- 189

#### 190 First Analysis: The Difference between Matched and Unmatched Outcome SMDs

In the first analysis, lead authors from five RCTs<sup>25,28,30–32</sup> were contacted, and three datasets acquired. Two RCTs provided sufficient information within their published papers, resulting in five RCTs analysed (1,033 participants). Two RCTs compared yoga to usual care,<sup>30</sup> and a waitlist control,<sup>28</sup> three RCTs tested supervised exercise programs in comparison to a brief intervention<sup>32</sup>, a home exercise and manipulative arm<sup>25</sup>, and prescribed NSAIDS<sup>31</sup>.

197

Of the five RCTs included, three had greater SMDs and statistical significance in favour of exercise compared to a control-arm when a matched secondary outcome was used in comparison to an unmatched primary outcome<sup>25,28,31</sup> (see Table 2). Of the three full datasets analysed, two demonstrated larger, statistically significant effects in favour of exercise with at least one matched secondary outcome at the primary time-point(s), compared to an unmatched primary outcome<sup>25,28</sup>. The analysis of Harris et al.<sup>32</sup> did not demonstrate any statistically significant differences using any
of the outcomes, but the use of the matched secondary outcome generated a greater
SMD in favour of the exercise group than when using the unmatched primary outcome.
The analysis of Tilbrook et al.<sup>30</sup> was the only trial analysed to demonstrate greater
between-arm differences when using an unmatched primary outcome.

209

# Table 2: First analysis results demonstrating the difference between matched and unmatched outcome SMDs

212

The original results and secondary analyses of the five RCTs are summarised in Figure 214 2: a pooled SMD of 0.19 (95% CI -0.03, 0.40; p=0.09) was seen for the unmatched 215 primary outcome, in comparison to the SMD of 0.30 (95% CI 0.04, 0.56; p=0.02) for 216 the first reported matched outcome. The subgroup differences (primary outcome 217 compared to the first matched outcome) were not statistically significant (SMD 0.11; 218 95% CI -0.34, 0.57; p=0.51).

219

# *Figure 2: Forest plot to demonstrate the pooled effect of the SMD for unmatched*

## 221 primary outcomes in comparison to matched secondary outcomes

222

# 223 <u>Second Analysis: Composite SMD calculations in comparison to Primary Outcome</u> 224 <u>SMDs</u>

In the second analysis, lead authors from seven  $RCTs^{25-28,33-35}$  were contacted, and four authors shared their datasets.<sup>25–28</sup> Four RCTs were analysed (864 participants):

one compared differing Pilates dosages plus advice versus advice alone,<sup>27</sup> one 227 compared yoga to a waitlist,<sup>28</sup> one tested supervised exercise programs in a home 228 exercise versus a manipulative arm,<sup>25</sup> and one compared McKenzie exercises versus 229 a physiotherapy intervention.<sup>26</sup> The composite outcomes varied in composition with 230 three composite outcomes formed of six outcomes<sup>25–27</sup> and one composite comprised 231 of three outcomes<sup>28</sup>. For example, Groessl et al.<sup>28</sup> measured the outcomes of strength, 232 flexibility and pain relief in their RCT which were matched to the treatment targets of 233 increasing strength and flexibility and improving pain tolerance. Please see Table 3 for 234 235 more detail regarding composition of composite outcomes.

236

The composite analysis impacted the results of three of four RCTs,<sup>25,26,28</sup> as seen in 237 238 Table 3. Three of the four analyses showed results with the composite outcome variable that had greater SMDs in favour of the exercise intervention<sup>25,26,28</sup>, of which 239 two<sup>25,28</sup> were (more) statistically significant in comparison to the original RCTs' primary 240 outcome results. All analyses showed a smaller standard error when using the 241 composite outcome. The use of the co-primary composite generated greater SMDs 242 than the composite outcome. However, the co-primary composite generated greater 243 SMDs (not statistically significant) than the primary outcome in one RCT,<sup>26</sup> but this was 244 not reproduced in the other RCT analysis.<sup>27</sup> 245

246

Table 3: Second analysis results of composite SMD calculations compared to
 primary outcome SMDs

This is summarised in Figure 3 whereby a pooled SMD of 0.24 (95% CI -0.04, 0.53; p=0.10) was seen for the primary outcome in comparison to the SMD of 0.28 (95% CI 0.05, 0.51; p=0.02) for the matched composite outcome. The subgroup differences (primary outcome compared to matched composite) were not statistically significant (SMD 0.03 (95% CI -0.13, 0.20) p=0.86).

# Figure 3: Summary plot to demonstrate pooled SMD of primary outcome in comparison to composite outcome

257

258 **Discussion** 

259

260 The results of these exploratory secondary analyses of previous RCTs of exercise for NSLBP suggest that it is possible that using a primary outcome matched to the 261 treatment targets of exercise may generate greater SMDs than a single unmatched 262 primary outcome. Further, using a composite outcome, matched to multiple exercise 263 treatment targets, may give greater power to detect superiority of exercise over a non-264 265 exercise control. In three of five RCTs, a single matched outcome measure generated a greater SMD than the original unmatched primary outcome SMD, and would impact 266 the results of four RCTs. In two of four RCTs, a composite matched outcome would 267 impact the results in favour of exercise versus control. Our analyses provide some 268 support for matching the primary outcome to the treatment targets of the exercise 269 intervention, and for considering the use of a composite outcome in comparison to a 270 271 single outcome when multiple exercise targets are identified. Using a matched outcome may provide more clinically meaningful results, and will allow for identification of 272 273 treatment interventions that may be more effective than previously supposed.

274

275 Treatment targets may be described as intermediate variables or surrogate outcomes, as they may sit on the pathway to a patient relevant outcome such as pain or function. 276 277 However, this may not always be the case, and the treatment targets reported by the authors of these RCTs may not have been based on clear programme development 278 theory or logic modelling.<sup>36,37</sup> Many of the treatment targets identified by the RCT 279 authors were captured by some of their outcomes, but there were no published 280 intervention development or programme evaluation<sup>38</sup> papers for any of the included 281 282 RCTs within which to test the degree that these treatment targets were indeed the focus of their intervention. Thus, it is difficult to identify which of the treatment targets 283 may have been prioritised, or which may have been changed by the exercise 284 285 interventions. In exercise, where multiple treatment targets are common, it is challenging without clear intervention theory, to understand how the exercise 286 intervention may have exerted its effect. Heneghan et al.<sup>39</sup> caution against the use of 287 288 surrogate outcomes as primary outcomes, without a clear understanding of the impact and effect of these upon patient-relevant outcomes. In the field of exercise and 289 NSLBP, the effect surrogate outcomes have on important patient outcomes like pain, 290 function and quality of life is poorly understood. Furthermore, there is a lack of 291 understanding as to what mechanisms of effect underpin exercise interventions for 292 NSLBP.40,41 293

294

The results of these exploratory secondary data analyses provide some support for considering the use of a composite matched outcome rather than a single unmatched outcome in trials of exercise for NSLBP. The results contrast with those from Parkes et al.<sup>42</sup> who compared a composite outcome (the Western Ontario and McMaster

299 Universities Osteoarthritis Index [WOMAC] score, pain and rescue medication) to a single outcome (WOMAC pain) in knee osteoarthritis. Their composite outcome 300 demonstrated modest improvements in responsiveness when compared to WOMAC 301 302 pain alone, but these were not statistically significant. While composite outcomes are uncommon as primary outcome measures in RCTs in the field of NSLBP, they are 303 frequently used in cardiovascular medicine, and have both advantages and 304 disadvantages. The use of a composite outcome can reduce the sample size,<sup>43,44</sup> which 305 is beneficial both for the recruitment period and associated costs of RCTs.45,46 306 307 However, in cardiovascular disease when a composite outcome included the outcome measures of most importance to patients, composite outcomes were less likely to 308 demonstrate a moderate treatment effect.<sup>46</sup> Moreover, there is a risk of overestimation 309 310 of treatment impact and effect when using composite outcomes if the component outcomes are not reported completely, leading to incorrect interpretation of the 311 results.<sup>39</sup> If the use of composite outcomes is to be considered in NSLBP, composite 312 313 outcomes would need to be chosen based on sound rationale. Furthermore, all outcomes selected to be included in the composite should individually be expected to 314 demonstrate an important effect, as any outcome that does not will dilute the overall 315 effect. Hence, composites make sense if the targeted outcomes all contribute to an 316 317 important treatment effect and are responsive to change. This proposal is supported 318 by our results that show the co-primary (matched) analysis produced the overall highest SMDs (greater than the composite). 319

320

Most RCTs of exercise for LBP appear to use a recommended core outcome domain<sup>47</sup> as a primary outcome.<sup>18</sup> Core outcome domains are necessary to allow for comparison of results across multiple datasets, and are useful for combined evidence approaches

324 such as meta-analysis. However, the authors of the LBP core outcome set highlight that the agreed domains do not restrict measurement or the choice of primary outcome. 325 but "mandate collection and reporting of the core outcome set alongside the outcomes 326 of interest".<sup>17</sup> It could be argued that prioritising pain or back-related disability as the 327 primary outcome domain in RCTs testing exercise for persistent NSLBP may not 328 accurately reflect the benefits of exercise, if these outcome domains do not match the 329 range of treatment targets of the intervention. The challenge of outcome measure 330 selection is encapsulated by Coster et al.,<sup>48</sup> "The ultimate value of a RCT ...will be 331 directly tied to how well the selected outcome measure matches the researcher's 332 understanding of what he or she expects to change, to what degree it is expected to 333 334 change, over what period of time this change will happen and how that change can 335 best be identified". As exercise is a complex intervention with multiple potential treatment targets, there are multiple possible outcomes that could be used, but multiple 336 outcomes should be interpreted with caution.<sup>49</sup> The proposed treatment targets of the 337 intervention should influence the selection of the primary outcome, from which the 338 minimally important difference is used to calculate the sample size.<sup>49</sup> Literature 339 regarding RCT design stipulates that the primary outcome should match the rationale 340 of the intervention.<sup>16,50</sup> The results of this analysis suggest that matching the primary 341 342 outcome to the treatment targets of the intervention may generate greater SMDs in 343 favour of exercise, and that a composite outcome comprised of the most important treatment targets could generate greater SMDs with smaller standard errors in favour 344 of exercise. A matched 'targeted' composite or single outcome may provide the RCT 345 346 team with the best chance of detecting the benefits of exercise compared to a control or comparator, as well as providing a clear framework for future testing of how exercise 347 may potentially achieve its effects. This may have clinical implications given we have 348

limited understanding of what components or targets of exercise are most influential increating change in outcomes of importance.

351

#### 352 Strengths and Limitations

353

This is the first study to explore the relationship between matched outcomes or 354 composite outcomes and the treatment targets of the exercise intervention in RCT 355 datasets of exercise for NSLBP. A strength of this study is the individual patient data 356 357 acquisition of seven previously published RCTs which allowed secondary analysis of 358 the data and generation of new composite variables. The analysis methods replicated the primary analysis method used by the trial teams of the individual RCTs, and this 359 ensured the data were comparable, strengthening the results of this analysis. These 360 RCTs were selected from a sample of RCTs included in a systematic review,<sup>18</sup> which 361 may have been subject to publication bias. The main limitation is that this was an 362 363 exploratory secondary analysis of a small number of RCT datasets. SMDs were chosen as a means to compare outcome estimates of different outcomes, but this may limit the 364 interpretability of the results as the SMD can be highly influenced by the SD of the 365 outcome data.<sup>51</sup> 366

367

#### 368 Implications for Clinicians and Researchers

369

370 Greater SMDs in favour of exercise interventions in RCTs for persistent NSLBP may

be derived from a combination of outcome measures rather than one alone in

determining treatment success, similar to the approach in the field of osteoarthritis.

373 <sup>52,21</sup> Greater SMD results may help to identify clinically meaningful treatments that 374 may have previously been overlooked due to selection of an unmatched primary outcome. Validation of these results is required in a larger sample of exercise trials in 375 376 NSLBP, and it would be interesting to explore the same issues for other complex interventions for NSLBP, and for other conditions. Clinicians and developers of 377 exercise interventions may wish to consider what their exercise intervention targets, 378 379 in order to select the most appropriate outcomes for that intervention. Further, it may be more beneficial for developers of RCT interventions to use a composite outcome 380 381 comprised of the most important outcomes targeted to the intervention being tested. We recommend that developers of exercise interventions consider logic models or 382 programme development theory<sup>36,37</sup> in order to map and guide assessment of the 383 384 mechanisms of action of their intervention, and the most likely outcomes to 385 accurately measure the changes expected. Previous intervention development has been exemplified by Hurley et al.<sup>37</sup> and Kjaer et al.<sup>53</sup> who provided detailed 386 descriptions of their self-management and exercise programs (please see Figure 4 387 as an example program model), including the 'active' components of the intervention, 388 the proposed determinants of change and the corresponding outcomes to capture 389 the intended change. It should be noted that we do not suggest all RCTs need to 390 consider this level of intervention development. However, considering the trial 391 392 intervention through a visual model can help to alleviate research waste by ensuring capture of the most important outcomes, and may contribute to future knowledge of 393 how these interventions may work. 394 Figure 4: An example program model of the GLA:D Back intervention, the 395

396 proposed patient achievements and the outcomes through the GLA:D Back

397 program, and their theoretical links (reproduced from Kjaer et al.<sup>53</sup> with
 398 permission)

399

400 **Conclusion** 

401

This study provides initial support that using i) a primary outcome matched to the treatment targets of the intervention may generate greater SMDs, and using ii) a composite outcome comprised of several outcomes matched to the exercise treatment targets, may generate greater SMDs and tighter estimates in favour of exercise interventions in comparison to a non-exercise arm in persistent NSLBP. Exercise prescribers and developers should consider the treatment targets of their intervention when selecting the most appropriate outcome(s).

#### 410 **References**

- 411 1. Buchbinder R, van Tulder M, Öberg B, et al. Low back pain: a call for action.
  412 *Lancet.* 2018;391(10137):2384-2388.
- 413 2. Hoy D, March L, Brooks P, et al. Measuring the global burden of low back
  414 pain. *Best Pract Res Clin Rheumatol.* 2010;24:155-165.
- 415 3. Hoy D, March L, Brooks P, et al. The global burden of low back pain: estimates
  416 from the Global Burden of Disease 2010 study. *Ann Rheum Dis.* 2014;0:1-7.
- 417 4. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for
- 418 non-surgical treatment of patients with recent onset low back pain or lumbar
  419 radiculopathy. *Eur Spine J.* 2018;27:60-75.
- 420 5. National Institute for Health and Care Excellence. *Low Back Pain and Sciatica*
- 421 in over 16s: Assessment and Management Assessment and Non-Invasive

422 Treatments Low Back Pain and Sciatica in over 16s.; 2016.

- 423 6. Babatunde OO, Jordan JL, Van der Windt DA, Hill JC, Foster NE, Protheroe J.
- 424 Effective treatment options for musculoskeletal pain in primary care: A
- 425 systematic overview of current evidence. Fleckenstein J, ed. *PLoS One*.

426 2017;12(6):e0178621.

427 7. Hayden JA, Ellis J, Ogilvie R, Malmivaara A, van Tulder MMW. Exercise

428 therapy for chronic low back pain. *Cochrane Database Syst Rev.* 

429 2021;CD009790:in press.

430 8. Hayden JA, Wilson MN, Stewart S, et al. Exercise treatment effect modifiers in

- 431 persistent low back pain: an individual participant data meta-analysis of 3514
- 432 participants from 27 randomised controlled trials On behalf of Chronic Low
- 433 Back Pain IPD Meta-Analysis Group. *Br J Sport Med*. 2019;0:1-16.
- 434 9. Searle A, Spink M, Ho A, Chuter V. Exercise interventions for the treatment of

- chronic low back pain: a systematic review and meta-analysis of randomised
  controlled trials. *Clin Rehabil.* 2015;29(12):1155-1167.
- 437 10. Naugle KM, Naugle KE, Riley JL, III. Reduced Modulation of Pain in Older
- 438 Adults After Isometric and Aerobic Exercise. *J Pain*. 2016;17(6):719-728.
- 439 11. Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH. Physical
- 440 activity and exercise for chronic pain in adults: an overview of Cochrane

441 Reviews. *Cochrane Database Syst Rev.* 2017;4(4):CD011279.

- 12. Steiger F, Wirth B, de Bruin ED, Mannion AF. Is a positive clinical outcome
- 443 after exercise therapy for chronic non-specific low back pain contingent upon a
- 444 corresponding improvement in the targeted aspect(s) of performance? A
- 445 systematic review. *Eur Spine J*. 2012;21(4):575-598.
- I3. Justice L, Sofka A, McGinty A. Targets, Techniques, and Treatment Contexts
  in Emergent Literacy Intervention. *Semin Speech Lang.* 2007;28(1):014-024.
- 448 14. Wood L, Ogilvie R, Hayden JA. Specifying the treatment targets of exercise
  449 interventions: do we? *Br J Sports Med.* 2020;54(20):1235-1236.
- 450 15. Chiarotto A, Terwee CB, Ostelo RW. Choosing the right outcome
- 451 measurement instruments for patients with low back pain. *Best Pract Res Clin*
- 452 *Rheumatol.* 2016;30(6):1003-1020.
- 453 16. Craig P, Matthews L, Moore L, Simpson S, Skivington K. Updated guidance:
- developing and evaluating complex interventions [draft of updated guidance forconsultation]. 2019:99.
- 456 17. Chiarotto A, Deyo RA, Terwee CB, et al. Core outcome domains for clinical
- 457 trials in non-specific low back pain. *Eur Spine J.* 2015;24(6):1127-1142.
- 458 18. Wood L, Foster NE, Lewis M, Bishop A. Exercise interventions for persistent
- 459 non-specific low back pain does matching outcomes to treatment targets

460 make a difference? A systematic review and meta-analysis. *J Pain*.

461 2021;22(2):107-126.

- 462 19. Watt H, Harris M, Noyes J, et al. Development of a composite outcome score
- 463 for a complex intervention measuring the impact of Community Health
- 464 Workers. *Trials*. 2015;16(1):107.
- 465 20. Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC. Definition,
- 466 reporting, and interpretation of composite outcomes in clinical trials:
- 467 Systematic review. *BMJ*. 2010;341(7769):381.
- 468 21. Deyo RA, Dworkin SF, Amtmann D, et al. Report of the NIH Task Force on
- research standards for chronic low back pain. *J Pain*. 2014;15(6):569-585.
- 22. Campbell N, Murray E. Designing and evaluating complex interventions to
- 471 improve health care. *BMJ*. 2007;334(7591):455-459.
- 472 23. Pogue J, Devereaux PJ, Thabane L, Yusuf S. Designing and analyzing clinical
- trials with composite outcomes: Consideration of possible treatment
- differences between the individual outcomes. *PLoS One*. 2012;7(4).
- 475 24. Sankoh AJ, D'Agostino RB, Huque MF. Efficacy endpoint selection and
- 476 multiplicity adjustment methods in clinical trials with inherent multiple endpoint
- 477 issues. *Stat Med*. 2003;22(20):3133-3150.
- 478 25. Bronfort G, Maiers MJ, Evans RL, et al. Supervised exercise, spinal
- 479 manipulation, and home exercise for chronic low back pain: A randomized
- 480 clinical trial. *Spine J*. 2011;11(7):585-598.
- 481 26. Moffett JK, Jackson DA, Gardiner ED, et al. Randomized trial of two
- 482 physiotherapy interventions for primary care neck and back pain patients:
- 483 "McKenzie" vs brief physiotherapy pain management. *Rheumatology*.
- 484 2006;45(12):1514-1521.

- 485 27. Miyamoto GC, Franco KFM, van Dongen JM, et al. Different doses of Pilates-
- 486 based exercise therapy for chronic low back pain: a randomised controlled trial
  487 with economic evaluation. *Br J Sports Med.* 2018;52:859-868.
- 488 28. Groessl EJ, Liu L, Chang DG, et al. Yoga for Military Veterans with Chronic
- 489 Low Back Pain: A Randomized Clinical Trial. *Am J Prev Med.* 2017;53(5):599490 608.
- 491 29. Song M-K, Lin F-C, Ward S, Fine J, Hill C. Composite Variables: When and
  492 How. *Nurs Res.* 2013;62(1):45-49.
- 30. Tilbrook HE, Cox H, Hewitt CE, et al. Yoga for Chronic Low Back Pain. Ann *Intern Med.* 2011;155(9):569-578.
- 31. Shirado O, Doi T, Akai M, et al. Multicenter randomized controlled trial to
  evaluate the effect of home-based exercise on patients with chronic low back
  pain: the Japan low back pain exercise therapy study. *Spine (Phila Pa 1976)*.
- 498 2010;35(17):E811-9.
- 499 32. Harris A, Moe TF, Eriksen HR, et al. Brief intervention, physical exercise and
- 500 cognitive behavioural group therapy for patients with chronic low back pain
- 501 (The CINS trial). *Eur J Pain (United Kingdom)*. 2017;21(8):1397-1407.
- 33. Maul I, Läubli T, Oliveri M, Krueger H. Long-term effects of supervised physical
  training in secondary prevention of low back pain. *Eur Spine J*.
- 504 2005;14(6):599-611.
- 505 34. Hildebrandt VH, Roper KI, Van den B, Douwes M, Van den Heuvel SG, Van
- 506 Buuren S. Cesar therapy is temporarily more effective than a standard
- 507 treatment from the general practitioner in patients with chronic aspecific lower
- 508 back pain; randomized, controlled and blinded study with a I year follow-up.
- 509 *Ned Tijdschr Geneeskd*. 2000;144(47 PG-2258-2264):2258-2264.

510 35. Chen HM, Wang HH, Chen CH, Hu HM. Effectiveness of a stretching exercise program on low back pain and exercise self-efficacy among nurses in Taiwan: 511 A randomized clinical trial. Pain Manag Nurs. 2014;15(1):283-291. 512 513 36. Rohwer A, Pfadenhauer L, Burns J, et al. Logic models help make sense of complexity in systematic reviews and health technology assessments. J Clin 514 515 Epidemiol. 2017;83:37-47. Hurley DA, Murphy LC, Hayes D, et al. Using intervention mapping to develop 516 37. 517 a theory-driven, group-based complex intervention to support self-518 management of osteoarthritis and low back pain (SOLAS). Implement Sci. 2016;11(1):56. 519 520 38. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex 521 interventions: Medical Research Council guidance. BMJ. 2015;350(19 6):h1258-h1258. 522 39. Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to 523 524 translate into benefits for patients. Trials. 2017;18(1):1-7. Helmhout PH, Staal JB, Maher CG, Petersen T, Rainville J, Shaw WS. 525 40. Exercise therapy and low back pain: insights and proposals to improve the 526 design, conduct, and reporting of clinical trials. Spine (Phila Pa 1976). 527 2008;33(16):1782-1788. 528 Rainville J, Hartigan C, Martinez E, Limke J, Jouve C, Finno M. Exercise as a 529 41. treatment for chronic low back pain. Spine J. 2004;4(1):106-115. 530 42. Parkes MJ, Callaghan MJ, Tive L, Lunt M, Felson DT. Responsiveness of 531 Single versus Composite Measures of Pain in Knee Osteoarthritis. J 532 *Rheumatol.* 2018;45(9):1308-1315. 533 534 43. Ross S. Composite outcomes in randomized clinical trials: arguments for and

- 535 against. *Am J Obstet Gynecol*. 2007;196(2):119.e1-119.e6.
- 536 44. Vaanholt MCW, Kok MM, von Birgelen C, Weernink MGM, van Til JA. Are
- component endpoints equal? A preference study into the practice of composite
  endpoints in clinical trials. *Heal Expect.* 2018;21(6):1046-1055.
- 539 45. Ferreira-González I, Permanyer-Miralda G, Busse JW, et al. Methodologic
- 540 discussions for using and interpreting composite endpoints are limited, but still
- identify major concerns. *J Clin Epidemiol*. 2007;60:651-657.
- 542 46. Ferreira-González I, Busse JW, Heels-Ansdell D, et al. Problems with use of
- composite end points in cardiovascular trials: Systematic review of randomised
  controlled trials. *BMJ*. 2007;334(7597):786-788.
- 545 47. Chiarotto A, Terwee CB, Deyo RA, et al. A core outcome set for clinical trials
  546 on non-specific low back pain: study protocol for the development of a core
  547 domain set. *Trials*. 2014;15(1):511.
- 548 48. Coster WJ. Making the Best Match: Selecting Outcome Measures for Clinical
- 549 Trials and Outcome Studies MeSH TERMS clinical trials as topic decision
- 550 making guidelines as topic outcome assessment (health care) treatment
- 551 outcome. *Am J Occup Ther*. 2013;67:162-170.
- 49. van Tulder M, Malmivaara A, Hayden J, Koes B. Statistical significance versus
  clinical importance: trials on exercise therapy for chronic low back pain as
  example. *Spine (Phila Pa 1976)*. 2007;32(16):1785-1790.
- 555 50. Chiarotto A, Ostelo RW, Turk DC, Buchbinder R, Boers M. Core outcome sets 556 for research and clinical practice. *Brazilian J Phys Ther*. 2017;21(2):77-84.
- 557 51. Faraone S V. Interpreting estimates of treatment effects: Implications for 558 managed care. *P T*. 2008;33(12).
- 559 52. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an

- 560 international initiative to improve outcome measurement in rheumatology. Trials. 2007;8:38. 561 53. Kjaer P, Kongsted A, Ris I, et al. GLA:D 
  Back group-based patient education 562 563 integrated with exercises to support self-management of back pain -Development, theories and scientific evidence - Development, t. BMC 564 565 Musculoskelet Disord. 2018;19(1):1-21. 566 **Figure Legends** 567 568
- 569 Figure 1: Processes of identification of suitable trials for inclusion and analysis

570 Figure 2: Forest plot to demonstrate the pooled effect of the SMD for unmatched

571 primary outcomes in comparison to matched secondary outcomes

572 Figure 3: Summary plot to demonstrate pooled SMD of primary outcome in

- 573 comparison to composite outcome
- 574 Figure 4: An example program model of the GLA:D Back intervention, the proposed

575 patient achievements and the outcomes through the GLA:D Back program, and their

theoretical links (reproduced from Kjaer et al., 2018, with permission)

577

Appendix

Click here to access/download Appendix Appendix 1.docx




Figure 1: Process of identification of suitable trials for inclusion and process of analysis

# Figure 2: Forest plot to demonstrate the pooled effect of the SMD for unmatched primary

### outcomes in comparison to matched secondary outcomes

Std. Mean Difference Std. Mean Difference									
Study or Subgroup	Std. Mean Difference	SE	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl				
17.1.1 Unmatched Prin	nary Outcomes								
Bronfort et al. (2011)	0.21	0.1429	10.2%	0.21 [-0.07, 0.49]	+ <b>-</b> -				
Groessl et al. (2017)	0.14	0.1633	9.3%	0.14 [-0.18, 0.46]					
Harris et al. (2017)	-0.16	0.1633	9.3%	-0.16 [-0.48, 0.16]					
Shirado et al. (2010)	0.18	0.1531	9.8%	0.18 [-0.12, 0.48]	_ <b>+</b> •				
Tilbrook et al. (2011) Subtotal (95% Cl)	0.5	0.1225	11.1% <b>49.8</b> %	0.50 [0.26, 0.74] <b>0.19 [-0.03, 0.40]</b>	<b>→</b>				
Heterogeneity: Tau <sup>2</sup> = 0	).04; Chi <sup>2</sup> = 10.95, df = 4	(P = 0.03	3); <b>P</b> = 63%	6					
Test for overall effect: Z	• •	<b>,</b>	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
17.1.2 Matched Secon	dary Outcomes								
Bronfort et al. (2011)	0.57	0.108	11.8%	0.57 [0.36, 0.78]					
Groessl et al. (2017)	0.23	0.1378	10.5%	0.23 [-0.04, 0.50]					
Harris et al. (2017)	0.1	0.2551	6.1%	0.10 [-0.40, 0.60]					
Shirado et al. (2010)	0.54	0.1429	10.2%	0.54 [0.26, 0.82]					
Tilbrook et al. (2011)	-0.01	0.1122	11.6%	-0.01 [-0.23, 0.21]					
Subtotal (95% CI)			50.2%	0.30 [0.04, 0.56]	◆				
Heterogeneity: Tau <sup>2</sup> = 0	).06; Chi <sup>2</sup> = 17.53, df = 4	(P = 0.00)	02); I <sup>2</sup> = 77	%					
Test for overall effect: Z	(= 2.29 (P = 0.02)								
Total (95% CI)			100.0%	0.24 [0.08, 0.41]	◆				
Heterogeneity: Tau <sup>2</sup> = 0	).05; Chi <sup>2</sup> = 29.66, df = 9	(P = 0.00	005); I <sup>2</sup> = 7	0%					
Test for overall effect: Z					-2 -1 U 1 2 Favours non-exercise Favours exercise				
Test for subgroup diffe	rences: Chi <sup>2</sup> = 0.43, df =	1 (P = 0.	51), <b>i²</b> = 09	%	Lavours non-exercise Favours exercise				

Std. is standard as part of SMD, SE is the standard error, IV is inverse variance, CI is confidence interval.


### Figure 3: Summary plot to demonstrate pooled SMD of primary outcome in comparison to

#### composite outcome

Study or Subgroup         Std. Mean Difference         SE         Weight         N, Random, 95% CI           22.1.1 Primary         Bronfort et al. (2011)         0.21         0.1429         10.9%         0.21 [-0.07, 0.49]           Groessl et al. (2017)         0.14         0.1633         10.0%         0.14 [-0.18, 0.46]           Miyamoto et al. (2018)         0.69         0.1633         10.0%         0.69 [0.37, 1.01]           Moffett et al. (2006)         -0.01         0.1071         12.6%         -0.01 [-0.22, 0.20]           Subtotal (95% CI)         43.5%         0.24 [-0.04, 0.53]				s	td. Mean Difference	Std. Mean Difference
Bronfort et al. (2011) 0.21 0.1429 10.9% 0.21 [-0.07, 0.49] Groessl et al. (2017) 0.14 0.1633 10.0% 0.44 [-0.18, 0.46] Miyamoto et al. (2018) 0.69 0.1633 10.0% 0.69 [0.37, 1.01] Moffett et al. (2006) -0.01 0.1071 12.6% -0.01 [-0.22, 0.20] Subtotal (95% CI) 43.5% 0.24 [-0.04, 0.53] Heterogeneity: Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 12.97, df = 3 (P = 0.005); l <sup>2</sup> = 77% Test for overall effect: $Z = 1.66$ (P = 0.10) 22.1.2 Composite Bronfort et al. (2011) 0.26 0.051 15.0% 0.26 [0.16, 0.36] Groessl et al. (2017) 0.3 0.0918 13.4% 0.30 [0.12, 0.48] Miyamoto et al. (2018) 0.6 0.102 12.9% 0.60 [0.40, 0.80] Moffett et al. (2006) 0 0.0408 15.3% 0.00 [-0.08, 0.08] Subtotal (95% CI) 56.5% 0.28 [0.05, 0.51] Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 40.16, df = 3 (P < 0.00001); l <sup>2</sup> = 93% Test for overall effect: $Z = 2.38$ (P = 0.02) Total (95% CI) 0.26 [0.09, 0.43] Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 53.30, df = 7 (P < 0.00001); l <sup>2</sup> = 87% Test for overall effect: $Z = 2.09$ (P = 0.002)	Study or Subgroup	Std. Mean Difference	SE	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Groessl et al. (2017)       0.14       0.1633       10.0%       0.14       [-0.18, 0.46]         Miyamoto et al. (2018)       0.69       0.1633       10.0%       0.69       [0.37, 1.01]         Moffett et al. (2006)       -0.01       0.1071       12.6%       -0.01       [-0.22, 0.20]         Subtotal (95% CI)       43.5%       0.24 [-0.04, 0.53]       -0.04       -0.05]         Heterogeneity: Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 12.97, df = 3 (P = 0.005); I <sup>2</sup> = 77%       -0.26 [0.16, 0.36]       -0.26 [0.16, 0.36]         Groessl et al. (2011)       0.26       0.051       15.0%       0.26 [0.16, 0.36]         Groessl et al. (2017)       0.3       0.0918       13.4%       0.30 [0.12, 0.48]         Miyamoto et al. (2018)       0.6       0.102       12.9%       0.60 [0.40, 0.80]         Moffett et al. (2018)       0       0.0408       15.3%       0.00 [-0.08, 0.08]         Subtotal (95% CI)       56.5%       0.28 [0.05, 0.51]       -         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 40.16, df = 3 (P < 0.00001); I <sup>2</sup> = 93%       -2       -1       0         Test for overall effect: Z = 2.38 (P = 0.02)       100.0%       0.26 [0.09, 0.43]       -2       -1       0	22.1.1 Primary					
Miyamoto et al. (2018) $0.69$ $0.1633$ $10.0\%$ $0.69$ $0.69$ $0.133$ $10.0\%$ $0.69$ $0.69$ $0.11$ $10.0\%$ $0.69$ $0.01$ $0.01$ $10.01$ $112.6\%$ $-0.01$ $0.01$ $0.01$ $0.22$ $0.20$ $0.24$ $0.004$ $0.53$ $0.24$ $0.04$ $0.53$ $0.24$ $0.04$ $0.53$ $0.24$ $0.04$ $0.53$ $0.24$ $0.04$ $0.53$ $0.24$ $0.04$ $0.53$ $0.24$ $0.04$ $0.53$ $0.24$ $0.04$ $0.53$ $0.24$ $0.04$ $0.53$ $0.26$ $0.053$ $0.26$ $0.06$ $0.053$ $0.26$ $0.053$ $0.06$ $0.026$ $0.06$ $0.026$ $0.060$ $0.048$ $0.60$ $0.026$ $0.060$	Bronfort et al. (2011)	0.21	0.1429	10.9%	0.21 [-0.07, 0.49]	+
Moffett et al. (2006)       -0.01       0.1071       12.6%       -0.01 [-0.22, 0.20]         Subtotal (95% CI)       43.5%       0.24 [-0.04, 0.53]         Heterogeneity: Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 12.97, df = 3 (P = 0.005); I <sup>2</sup> = 77%         Test for overall effect: Z = 1.66 (P = 0.10)         22.1.2 Composite         Bronfort et al. (2011)       0.26       0.051       15.0%       0.26 [0.16, 0.36]         Groessl et al. (2017)       0.3       0.0918       13.4%       0.30 [0.12, 0.48]         Miyamoto et al. (2018)       0.6       0.102       12.9%       0.60 [0.40, 0.80]         Moffett et al. (2006)       0       0.0408       15.3%       0.00 [-0.08, 0.08]         Subtotal (95% CI)       56.5%       0.28 [0.05, 0.51]       +         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 40.16, df = 3 (P < 0.00001); I <sup>2</sup> = 93%       -2       -1       0         Test for overall effect: Z = 2.38 (P = 0.02)       100.0%       0.26 [0.09, 0.43]       +         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 53.30, df = 7 (P < 0.00001); I <sup>2</sup> = 87%       -2       -1       0	Groessl et al. (2017)	0.14	0.1633	10.0%	0.14 [-0.18, 0.46]	- <b>+</b>
Subtotal (95% CI)       43.5%       0.24 [-0.04, 0.53]         Heterogeneity: Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 12.97, df = 3 (P = 0.005); l <sup>2</sup> = 77%       Test for overall effect: $Z = 1.66$ (P = 0.10)         22.1.2 Composite       Bronfort et al. (2011)       0.26       0.051       15.0%       0.26 [0.16, 0.36]         Groessl et al. (2017)       0.3       0.0918       13.4%       0.30 [0.12, 0.48]       Image: constant of the state of the stat	Miyamoto et al. (2018)	0.69	0.1633	10.0%	0.69 [0.37, 1.01]	<b>_</b>
Heterogeneity: Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 12.97, df = 3 (P = 0.005); l <sup>2</sup> = 77% Test for overall effect: Z = 1.66 (P = 0.10) <b>22.1.2 Composite</b> Bronfort et al. (2011) 0.26 0.051 15.0% 0.26 [0.16, 0.36] Groessl et al. (2017) 0.3 0.0918 13.4% 0.30 [0.12, 0.48] Miyamoto et al. (2018) 0.6 0.102 12.9% 0.60 [0.40, 0.80] Moffett et al. (2006) 0 0.0408 15.3% 0.00 [-0.08, 0.08] <b>Subtotal (95% Cl)</b> 56.5% 0.28 [0.05, 0.51] Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 40.16, df = 3 (P < 0.00001); l <sup>2</sup> = 93% Test for overall effect: Z = 2.38 (P = 0.02) Total (95% Cl) 100.0% 0.26 [0.09, 0.43] Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 53.30, df = 7 (P < 0.00001); l <sup>2</sup> = 87%	Moffett et al. (2006)	-0.01	0.1071	12.6%	-0.01 [-0.22, 0.20]	
Test for overall effect: $Z = 1.66 (P = 0.10)$ <b>22.1.2 Composite</b> Bronfort et al. (2011)       0.26       0.051       15.0%       0.26 [0.16, 0.36]         Groessl et al. (2017)       0.3       0.0918       13.4%       0.30 [0.12, 0.48]         Miyamoto et al. (2018)       0.6       0.102       12.9%       0.60 [0.40, 0.80]         Moffett et al. (2006)       0       0.0408       15.3%       0.00 [-0.08, 0.08]         Subtotal (95% CI)       56.5%       0.28 [0.05, 0.51]         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 40.16, df = 3 (P < 0.00001); I <sup>2</sup> = 93%         Test for overall effect: $Z = 2.38 (P = 0.02)$ Total (95% CI)       100.0%       0.26 [0.09, 0.43]         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 53.30, df = 7 (P < 0.00001); I <sup>2</sup> = 87%       -1	Subtotal (95% CI)			43.5%	0.24 [-0.04, 0.53]	◆
<b>22.1.2 Composite</b> Bronfort et al. (2011) $0.26$ $0.051$ $15.0\%$ $0.26$ $[0.16, 0.36]$ Groessl et al. (2017) $0.3$ $0.0918$ $13.4\%$ $0.30$ $[0.12, 0.48]$ Miyamoto et al. (2018) $0.6$ $0.102$ $12.9\%$ $0.60$ $[0.40, 0.80]$ Moffett et al. (2006) $0$ $0.0408$ $15.3\%$ $0.00$ $[-0.08, 0.08]$ Subtotal (95% Cl) $56.5\%$ $0.28$ [0.05, 0.51] $\bullet$ Heterogeneity: Tau <sup>2</sup> = $0.05$ ; Chi <sup>2</sup> = $40.16$ , df = $3$ (P < $0.00001$ ); I <sup>2</sup> = $93\%$ $\bullet$ $\bullet$ Total (95% Cl) $100.0\%$ $0.26$ [0.09, $0.43$ ] $\bullet$ Heterogeneity: Tau <sup>2</sup> = $0.05$ ; Chi <sup>2</sup> = $53.30$ , df = 7 (P < $0.00001$ ); I <sup>2</sup> = $87\%$ $-2$ $-1$ $0$	Heterogeneity: Tau <sup>2</sup> = 0.	.07; Chi <sup>z</sup> = 12.97, df = 3 (i	P = 0.005	5); I² = 77%		
Bronfort et al. (2011)       0.26       0.051       15.0%       0.26 [0.16, 0.36]         Groessl et al. (2017)       0.3       0.0918       13.4%       0.30 [0.12, 0.48]         Miyamoto et al. (2018)       0.6       0.102       12.9%       0.60 [0.40, 0.80]         Moffett et al. (2006)       0       0.0408       15.3%       0.00 [-0.08, 0.08]         Subtotal (95% CI)       56.5%       0.28 [0.05, 0.51]         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 40.16, df = 3 (P < 0.00001); I <sup>2</sup> = 93%         Test for overall effect: Z = 2.38 (P = 0.02)         Total (95% CI)       100.0%       0.26 [0.09, 0.43]         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 53.30, df = 7 (P < 0.00001); I <sup>2</sup> = 87%       -2         -1       0       1	Test for overall effect: Z	= 1.66 (P = 0.10)				
Groessl et al. (2017)       0.3       0.0918       13.4%       0.30 [0.12, 0.48]         Miyamoto et al. (2018)       0.6       0.102       12.9%       0.60 [0.40, 0.80]         Moffett et al. (2006)       0       0.0408       15.3%       0.00 [-0.08, 0.08]         Subtotal (95% CI)       56.5%       0.28 [0.05, 0.51]         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 40.16, df = 3 (P < 0.00001); I <sup>2</sup> = 93%         Test for overall effect: Z = 2.38 (P = 0.02)         Total (95% CI)       100.0%       0.26 [0.09, 0.43]         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 53.30, df = 7 (P < 0.00001); I <sup>2</sup> = 87%       -2         -1       0       1	22.1.2 Composite					
Miyamoto et al. (2018)       0.6       0.102       12.9%       0.60 [0.40] 0.80]         Moffett et al. (2006)       0       0.00408       15.3%       0.00 [-0.08, 0.08]         Subtotal (95% CI)       56.5%       0.28 [0.05, 0.51]         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 40.16, df = 3 (P < 0.00001); I <sup>2</sup> = 93%         Test for overall effect: Z = 2.38 (P = 0.02)         Total (95% CI)       0.00%         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 53.30, df = 7 (P < 0.00001); I <sup>2</sup> = 87%         -2       -1         -2       -1	Bronfort et al. (2011)	0.26	0.051	15.0%	0.26 [0.16, 0.36]	-
Moffett et al. (2006)       0       0       0.0408       15.3%       0.00 [-0.08, 0.08]         Subtotal (95% CI)       56.5%       0.28 [0.05, 0.51]         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 40.16, df = 3 (P < 0.00001); I <sup>2</sup> = 93%         Test for overall effect: Z = 2.38 (P = 0.02)         Total (95% CI)       100.0%       0.26 [0.09, 0.43]         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 53.30, df = 7 (P < 0.00001); I <sup>2</sup> = 87%       -2       -1         Tost for overall effect: 7 = 3.08 (P = 0.002)       -2       -1       0	Groessl et al. (2017)	0.3	0.0918	13.4%	0.30 [0.12, 0.48]	
Subtotal (95% CI)       56.5%       0.28 [0.05, 0.51]         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 40.16, df = 3 (P < 0.00001); I <sup>2</sup> = 93%       0.26 [0.09, 0.43]         Total (95% CI)       100.0%       0.26 [0.09, 0.43]         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 53.30, df = 7 (P < 0.00001); I <sup>2</sup> = 87%       -2       -1         Total (95% CI)       -2       -1       0	Miyamoto et al. (2018)	0.6	0.102	12.9%	0.60 [0.40, 0.80]	
Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 40.16, df = 3 (P < 0.00001); I <sup>2</sup> = 93% Test for overall effect: Z = 2.38 (P = 0.02) <b>Total (95% Cl) 100.0% 0.26 [0.09, 0.43]</b> Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 53.30, df = 7 (P < 0.00001); I <sup>2</sup> = 87% -2 -1 0 1	Moffett et al. (2006)	0	0.0408	15.3%	0.00 [-0.08, 0.08]	+
Test for overall effect: Z = 2.38 (P = 0.02)         Total (95% Cl)       100.0%         Heterogeneity: Tau² = 0.05; Chi² = 53.30, df = 7 (P < 0.00001); I² = 87%	Subtotal (95% CI)			56.5%	0.28 [0.05, 0.51]	◆
Total (95% Cl)       100.0%       0.26 [0.09, 0.43]         Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 53.30, df = 7 (P < 0.00001); I <sup>2</sup> = 87%       -2       -1       0       1         Total (offset: 7 = 2.08 (P = 0.002)       -2       -1       0       1	Heterogeneity: Tau <sup>2</sup> = 0.	.05; Chi <sup>2</sup> = 40.16, df = 3 (	P < 0.000	)01); I <sup>z</sup> = 93	%	
Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 53.30, df = 7 (P < 0.00001); I <sup>2</sup> = 87%	Test for overall effect: Z	= 2.38 (P = 0.02)				
Tact for everall effect: $7 = 2.08 (P = 0.002)$ -2 -1 U 1	Total (95% CI)			100.0%	0.26 [0.09, 0.43]	◆
Test for everall effect: $7 = 2.09 (B = 0.002)$ -2 -1 U 1	Heterogeneity: Tau <sup>2</sup> = 0.	.05; Chi <sup>2</sup> = 53.30, df = 7 (	P < 0.000	001); I <sup>2</sup> = 87	%	
Equation of order of the sector of the secto						-2 -1 U 1 Favours control Favours exercise
Test for subgroup differences: Chi <sup>2</sup> = 0.03, df = 1 (P = 0.86), i <sup>2</sup> = 0%	Test for subgroup differ	ences: Chi² = 0.03, df = 1	(P = 0.8	6), I² = 0%		Favours control Favours exercise

Std. represents standard as part of SMD, SE is standard error, IV is inverse variance, CI is confidence interval.

Figure 4: An example program model of the GLA:D Back intervention, the proposed patient achievements and the outcomes through the GLA:D Back program, and their theoretical links (reproduced from Kjaer et al., 2018, under the Creative Commons licence with permission)



# Table 1: Included Trial Datasets

Analysis		Trial	Intervention	Control	Exercise	Outcome Domains		Primary	Analysis F	Performed
					Treatment	All	Matched	Time-	Primary	Secondary
					Targets	Primary	Secondary	Point	Outcome	Outcome
		Shirado	Exercise	NSAIDs	Increasing	Self-	<u>Objectively</u>	8 weeks		
		et al.,			overall	<u>reported:</u>	<u>recorded:</u>			
		2011 <sup>1</sup>			physical	Pain	Flexibility			
					activity;	intensity	(finger floor			
YSIS					spinal	(VAS),	distance)		Only SMD analysis	
FIRST ANALYSIS					mobility	Physical			performed	anaryoio
RST /						function				
∣≣						(RMDQ)				
						and				
						Health-				
						related				

				quality of				
				life (JLEQ)				
Tilbrook	Yoga	Usual	Improving	<u>Self-</u>	<u>Self-reported:</u>	12 weeks		
et al.,		care	mobility;	<u>reported:</u>	Pain intensity			
2011 <sup>2</sup>			strength;	Physical	(Aberdeen			
			posture;	function	Back Pain			
			reducing pain	(RMDQ)	Scale)			
Harris et	Brief	Brief	Fear	<u>Objectively</u>	<u>Self-reported:</u>	12	Difference	ANOVA
al.,	intervention	intervent	avoidance	<u>recorded:</u>	Fear-	months	s between	
2017 <sup>3</sup>	with physical	ion	and	Increased	avoidance		groups	
	activity		movement	work	behaviours		were	
			phobia; re-	participatio	(Fear-		measured	
			establish	n –	Avoidance		with chi-	
			normal	change	Beliefs		square	
			movement	form full-	Questionnaire		tests for	
			patterns	time sick	)		each of	

					leave to			the 12	
					partial sick			months	
					leave or				
					full return				
					to work				
	Bronfort	Supervised	Spinal	Increase	<u>Self-</u>	<u>Objectively</u>	12	Analysis	Change
	et al.,	exercise	manipul	trunk muscle	reported:	<u>recorded:</u>	weeks*	of	scores for
	20114		ation	endurance;	Pain	Static		covarianc	trunk
<u>S</u>			(Home	increase	intensity	endurance		е	performanc
ΓΥS			exercise	trunk stability	(11-point	(flexion,		(ANCOVA	е
ANA			and		box scale)	extension),		) for	measures
SECOND ANALYSIS			advice)			dynamic		difference	were used
SEC						endurance		s between	and then
						(flexion,		the three	analysed
						extension),		groups	for group
						isometric		and linear	differences

						strength		mixed-	with
						(flexion,		model	analysis of
						extension).			variance
									(ANOVA)
	Groessl	Yoga	Waitlist	Increase	Self-	Self-reported:	12 weeks	Linear mixe	ed-model
	et al.,		control	strength and	<u>reported:</u>	Pain <mark>intensity</mark>			
	2017 <sup>5</sup>			flexibility;	Physical	(BPI)			
				reduce	function	(reported);			
/SIS				stress;	(RMDQ)	<u>Objectively</u>			
NALY				increased		<u>recorded:</u>			
SECOND ANALYSIS				pain		Range of			
ECO				tolerance		motion			
SI						(Saunders			
						digital			
						inclinometer)			
						and core			

						strength		
						(prone and		
						supine		
						bridge) (not		
						reported in		
						RCT paper)		
	Miyamot	Pilates once	Advice	Improving	Self-	<u>Self-reported</u> :	6 weeks	Liner mixed-model
	o et al.,	a week, twice	alone	disability;	<u>reported</u> :	Physical		
	2018 <sup>6</sup>	a week and		reducing	Pain	Function		
		three times a		absence from	intensity	(PSFS),		
		week plus		work;	(NRS),	Global		
		advice		physical and	Physical	Perceived		
				functional	function	Effect,		
				recovery;	(RMDQ)	Catastrophizi		
				reduce pain;		ng (PCS),		
				improve		Kinesiophobi		

				catastrophisi		a (TSK),		
				ng and		Health-		
				kinesiophobia		related		
						Quality of Life		
						(HRQoL)		
						(SF6D)		
	Moffett	McKenzie	Solution	Fear of	<u>Self-</u>	Self-reported:	6 weeks*	Linear mixed-model
	et al.,	exercise	finding	physical	<u>reported:</u>	Health control		
	20067		approac	activity;	Fear	(Multidimensi		
			h	relieve pain;	avoidance	onal health		
				reduce	(TSK),	locus of		
				anxiety and	Physical	control),		
				depression;	function	Self-efficacy		
				help them	(RMDQ)	(PSEQ),		
				take control		Anxiety and		
				of their				

	situation;	Depression		
	enable the	(HADS)		
	individual to			
	cope better;			
	return to their			
	normal			
	activities			
	sooner;			
	prevent long-			
	term disability			
	prevent long- term disability	 . 7		

Legend: Only matched secondary outcomes are listed here. \*Bronfort et al. <sup>4</sup> and Moffett et al. <sup>7</sup> did not specify their primary time-point, thus the first time-point post-treatment was used, as per the method used in the systematic review<sup>8</sup>. Abbreviations used: NSAIDs non-steroidal anti-inflammatories; VAS Visual Analogue Scale; RMDQ Roland and Morris Disability Questionnaire; JLEQ Japan Low Back Pain Evaluation Questionnaire; SMD Standardised Mean Difference; ANOVA Analysis of Variance; ANCOVA Analysis of Covariance; BPI Brief Pain Inventory; NRS Numeric Rating Scale; PSFS Patient Specific Functional Scale; PCS Pain Catastrophising Scale; TSK Tampa Scale of Kinesiophobia; SF6D Short-Form 6-Dimension questionnaire; PSEQ Pain Self-Efficacy Questionnaire; HADS Hospital Anxiety and Depression Scale.

Table 2: First analysis results demonstrating the difference between matched and unmatched outcome SMDs

Trial	Comparator	Outcome Domain	Standardised	
		(Primary Outcome	Mean Difference	р
		Shaded)	(95%	<b>Jethc</b>
			Confidence	Analysis Method
			Interval)	Anal
Shirado et	Exercise vs	Pain <mark>intensity</mark>	0.17 (-0.12, 0.47)	
al., 2010 <sup>30</sup>	NSAIDS			
		Physical function	0.27 (-0.02, 0.55)	
		Health-related quality of	0.29 (-0.00, 0.57)	-
		life		Data
		Forward finger	0.54 (0.26, 0.83)	hed [
		distance*		Published Data
Tilbrook et	Yoga vs Usual	Physical function	0.50 (0.26, 0.74)	
al., 2011 <sup>31</sup>	care			
		Pain intensity	-0.01 (-0.23,	
			0.22)	
Bronfort et	Exercise vs	Pain <mark>intensity</mark>	0.21 (-0.07, 0.5)	
al., 2011 <sup>25</sup>	Manipulation			
		Static endurance	0.55 (0.32, 0.79)	odel
		flexion*		Linear Mixed Model
		Static endurance	0.31 (0.09, 0.52)	r Mix
		extension*		Linea

		Dynamic endurance	0.56 (0.34, 0.78)	
		flexion*		
		Dynamic endurance	0.84 (0.62, 1.05)	-
		extension*		
		Isometric strength	0.15 (-0.00, 0.31)	-
		flexion*		
		Isometric strength	0.17 (0.02, 0.32)	-
		extension*		
Bronfort et	Exercise vs	Pain <mark>intensity</mark>	0.21 (-0.07, 0.5)	
al., 2011 <sup>25</sup>	Manipulation			
		Static endurance	0.57 (0.31, 0.83)	
		flexion*		
		Static endurance	0.32 (0.08, 0.57)	-
		extension*		
		Dynamic endurance	0.59 (0.34, 0.83)	AVG
		flexion*		ANCOVA
		Dynamic endurance	0.84 (0.61, 1.07)	
		extension*		
		Isometric strength	0.20 (0.01, 0.38)	-
		flexion*		
		Isometric strength	0.19 (0.00, 0.37)	1
		extension*		
Groessl et	Yoga vs Waiting	Physical function	0.14 (-0.27, 0.55)	eq
al., 2017 <sup>28</sup>	list			r Mix
		Pain <mark>intensity</mark>	0.30 (0.08, 0.52)	Linear Mixed

		Plank*	0.23 (-0.04, 0.51)	
		Flexion ROM*	0.27 (-0.08, 0.61)	
		Extension ROM*	0.08 (-0.28, 0.44)	
Harris et	Physical	Return to work*	-0.16 (-0.32, -	
al., 2017 <sup>32</sup>	exercise vs Brief		0.00)	
	intervention only			Chi <sup>2</sup>
		Fear avoidance (work)	-0.29 (-0.64,	
			0.06)	
		Fear avoidance	0.01 (-0.31, 0.33)	A/
		(physical activity)		ANOVA

NSAIDS is non-steroidal anti-inflammatory drugs; ANOVA is analysis of variance; ANCOVA is analysis of covariance; ROM is range of motion; Outcomes shaded in grey are unmatched primary outcomes identified by trial authors. All outcomes were selfreported measures, apart from \*, which were objectively measured. Table 3: Second analysis results of composite SMD calculations compared to

primary outcome SMDs

Primary	Trial	Primary	Outcome	SMD	Sig. (at	Conclusion
Outcome		Time-		(Brackets	p<0.05)	
Classification		Point		denote		
				95%		
				confidence		
				intervals)		
Matched	Miyamoto	6 weeks	Primary	0.69 (0.4,	<0.0001	No change
	et al.		(Pain	1.0)		
	2018 <sup>27</sup>		<mark>intensity</mark> )			
			Composite*	0.60 (0.4,	<0.0001	
				0.8)		
			Co-primary	0.62 (0.37,	<0.0001	
			composite	0.86)		
	Moffett et	6 weeks	Primary	-0.01	NS	No change
	al. 2006 <sup>26</sup>		(Fear	(-		
			Avoidance	0.22,0.20)		
			Beliefs)			
			Composite°	0.00	NS	
				(-0.08,0.08)		
			Co-primary	0.08	NS	
			composite	(-0.13,0.29)		

Bronfort	12	Primary	0.21 (-0.07,	Not	Changed
et al.,	weeks	(Pain	0.5)	reported	results in
2011 <sup>25</sup>		Intensity)			favour of
		Composite <sup>¥</sup>	0.26	<0.0001	exercise
		(ANCOVA)	(0.16,0.36)		
		Composite <sup>¥</sup>	0.43 (0.31,	<0.0001	
		(LMM)	054)		
Groessl	12	Primary	0.14	NS	Changed
et al.,	weeks	(Physical	(-0.46,0.18)		results in
2017 <sup>28</sup>		Function)			favour of
		Composite§	0.30 (0.08,	0.007	exercise
			0.52)		
	et al., 2011 <sup>25</sup> Groessl et al.,	et al., weeks 2011 <sup>25</sup> Groessl 12 et al., weeks	et al., weeks (Pain 2011 <sup>25</sup> Intensity) Composite <sup>¥</sup> (ANCOVA) Composite <sup>¥</sup> (LMM) Groessl 12 Primary et al., weeks (Physical 2017 <sup>28</sup> Function)	et al., weeks (Pain 0.5) $2011^{25}$ Intensity) Composite <sup>¥</sup> 0.26 (ANCOVA) (0.16,0.36) Composite <sup>¥</sup> 0.43 (0.31, (LMM) 054) Groessl 12 Primary 0.14 et al., weeks (Physical (-0.46,0.18) $2017^{28}$ Function) Composite <sup>§</sup> 0.30 (0.08,	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$

Where NS is non-significant, SMD is standardised mean difference, LMM is linear mixed model, ANCOVA is analysis of variance with co-variates. The composite outcomes were comprised of: \*Miyamoto et al. pain, physical function, pain catastrophising, fear-avoidance beliefs, global perceived effect and a patient-specific functional scale); \*Moffett et al. fear-avoidance beliefs, physical function, health control, self-efficacy, anxiety and depression; <sup>¥</sup>Bronfort et al. dynamic endurance flexion and extension strength, static endurance flexion and extension strength, static endurance flexion and extension strength; <sup>§</sup>Groessl et al. strength, flexibility and pain relief.

Click here to access/download ICMJE Form LW ICMJ form.docx Click here to access/download ICMJE Form GM ICMJ form.docx Click here to access/download ICMJE Form CH ICMJ form.docx Click here to access/download ICMJE Form SR ICMJ form.docx Click here to access/download ICMJE Form EG ICMJ form.docx Click here to access/download ICMJE Form GB ICMJ form.docx Click here to access/download ICMJE Form ML ICMJ form.docx Click here to access/download ICMJE Form AB ICMJ form.docx Click here to access/download ICMJE Form NF ICMJ form.docx



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	ltem No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	1,2
Introduction			
Background and	2a	Scientific background and explanation of rationale	3,4
objectives	2b	Specific objectives or hypotheses	4,5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5,8, 9,10
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Participants	4a	Eligibility criteria for participants	5
	4b	Settings and locations where the data were collected	NA
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	NA
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	5,6
	6b	Any changes to trial outcomes after the trial commenced, with reasons	NA
Sample size	7a	How sample size was determined	NA
	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
Randomisation:			
Sequence	8a	Method used to generate the random allocation sequence	NA
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	NA
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	NA
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	NA

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	8,9,10
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	6,7
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	6,7
Results			
Participant flow (a diagram is strongly	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	8, figure 1,
recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons	NA
Recruitment	14a	Dates defining the periods of recruitment and follow-up	NA
	14b	Why the trial ended or was stopped	NA
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	NA
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	Figure 2
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Figure 2, 3
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	NA
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	NA
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	NA
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	14
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	15
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	15
Other information			
Registration	23	Registration number and name of trial registry	Title page
Protocol	24	Where the full trial protocol can be accessed, if available	NA
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	Title page

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see <a href="http://www.consort-statement.org">www.consort-statement.org</a>.

Archives Submission Checklist

Click here to access/download Archives Submission Checklist APMR\_Checklist Final July 2017 (1).docx